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Background: Digital breast tomosynthesis (DBT) is a three-dimensional mammography technique with the
potential to improve accuracy by improving differentiation between malignant and non-malignant lesions.
Objectives: The objectives of the study were to compare the diagnostic accuracy of DBT in conjunction
with two-dimensional (2D) mammography or synthetic 2D mammography, against standard 2D
mammography and to determine if DBT improves the accuracy of detection of different types of lesions.
Study population: Women (aged 47–73 years) recalled for further assessment after routine breast
screening and women (aged 40–49 years) with moderate/high of risk of developing breast cancer
attending annual mammography screening were recruited after giving written informed consent.
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Intervention: All participants underwent a two-view 2D mammography of both breasts and two-view
DBT imaging. Image-processing software generated a synthetic 2D mammogram from the DBT data sets.
Retrospective reading study: In an independent blinded retrospective study, readers reviewed
(1) 2D or (2) 2D+DBT or (3) synthetic 2D+DBT images for each case without access to original screening
mammograms or prior examinations. Sensitivities and specificities were calculated for each reading arm
and by subgroup analyses.
Results: Data were available for 7060 subjects comprising 6020 (1158 cancers) assessment cases
and 1040 (two cancers) family history screening cases. Overall sensitivity was 87% [95% confidence
interval (CI) 85% to 89%] for 2D only, 89% (95% CI 87% to 91%) for 2D+DBT and 88% (95% CI 86%
to 90%) for synthetic 2D+DBT. The difference in sensitivity between 2D and 2D+DBT was of borderline
significance (p= 0.07) and for synthetic 2D+DBT there was no significant difference (p= 0.6). Specificity
was 58% (95% CI 56% to 60%) for 2D, 69% (95% CI 67% to 71%) for 2D+DBT and 71% (95% CI
69% to 73%) for synthetic 2D+DBT. Specificity was significantly higher in both DBT reading arms for
all subgroups of age, density and dominant radiological feature (p< 0.001 all cases). In all reading arms,
specificity tended to be lower for microcalcifications and higher for distortion/asymmetry. Comparing
2D+DBT to 2D alone, sensitivity was significantly higher: 93% versus 86% (p< 0.001) for invasive
tumours of size 11–20mm. Similarly, for breast density 50% or more, sensitivities were 93% versus
86% (p= 0.03); for grade 2 invasive tumours, sensitivities were 91% versus 87% (p= 0.01); where the
dominant radiological feature was a mass, sensitivities were 92% and 89% (p= 0.04) For synthetic
2D+DBT, there was significantly (p= 0.006) higher sensitivity than 2D alone in invasive cancers of size
11–20mm, with a sensitivity of 91%.
Conclusions: The specificity of DBT and 2D was better than 2D alone but there was only marginal
improvement in sensitivity. The performance of synthetic 2D appeared to be comparable to standard 2D.
If these results were observed with screening cases, DBT and 2D mammography could benefit to the
screening programme by reducing the number of women recalled unnecessarily, especially if a synthetic
2D mammogram were used to minimise radiation exposure. Further research is required into the feasibility
of implementing DBT in a screening setting, prognostic modelling on outcomes and mortality,
and comparison of 2D and synthetic 2D for different lesion types.
Study registration: Current Controlled Trials ISRCTN73467396.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will
be published in full in Health Technology Assessment; Vol. 19, No. 4. See the HTA programme website
for further project information.
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Glossary
Aetna A US health-care company providing a wide range of health-care products and services including
diagnostic tests and medical treatment.
BRCA gene status An inherited genetic mutation of either the BRCA1 or the BRCA2 gene affecting the
production of tumour suppressor proteins. Damage to deoxyribonucleic acid can result in genetic
alterations and significantly increases the lifetime risk of developing breast cancer.
Breast Imaging Reporting and Data System scale A widely accepted risk assessment and quality
assurance tool in mammography, particularly in the USA. A scale of numerical codes (0–6) is used
to indicate a film reader’s level of suspicion of malignancy.
DCMTK (Toolkit from dicom.offis.de) A software application widely used in hospitals and as a tool for
research projects to convert and store Digital Imaging and Communication in Medicine image files and
software servers.
Diagnostic Reference Levels The Ionising Radiation (Medical Exposure) Regulations 2000 requiring
all UK hospitals to adhere to safe diagnostic radiation standards and levels.
Estimated mean glandular dose An estimation of the radiation dose received in an exposure based
on the assumption that the breast comprises equal proportions of adipose and fibroglandular tissue.
Hologic SecurView DX Workstation Visual display of digital images on monitors optimised to read
two-dimensional and three-dimensional images.
Hologic Selenia Dimensions System Chosen manufacturer’s model of mammography imaging system
used in this trial to acquire two-dimensional and digital breast tomosynthesis images.
Interval cancer A cancer detected and diagnosed in the interval between a routine screening
mammogram and the subsequent routine screen. The cancer may have been present at initial
screening (false negative) or as a result of rapid growth in the interval period between screening
and detection.
International Workshop on Digital Mammography International workshop allowing discussion
of innovative mammography, tomosynthesis, computed tomography, magnetic resonance imaging
and computer-aided detection imaging and image-processing technologies.
Lymph node status Measure of the extent of axillary lymph node involvement in cases where breast
cancer spreads through the lymphatic system, outside the breast.
MACRO The electronic data capture and management system widely employed in clinical research
to store and manage data collected on forms.
Mammographic density This refers to the proportion of fibroglandular tissue in the breast and
low-density fatty breast tissue.
Microcalcification clusters Tiny calcium deposits detected on a mammogram and visualised primarily
as fine white flecks. The size, shape and pattern of these clusters are significant in determining potential
for malignancy.
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National Co-ordinating Centre for the Physics of Mammography National body that monitors image
quality and ensures imaging performance meets minimum NHS Breast Screening Programme standards
for image quality.
PERFORMS (PERsonal perFORmance in Mammographic Screening) System designed to assess the image
interpretation skills and provide ongoing education to film readers working in the national breast screening
programme. Annual self-assessment of a caseload of screening mammograms is undertaken and feedback
provided on diagnostic accuracy.
Sensitivity of mammography The percentage of breast cancers that are actually detected by
mammography in a given population of women, which are true cancers.
Specificity of mammography The percentage of negative results for breast cancer in a given population
of women who do not have the disease.
Synthetic two-dimensional image Simulated two-dimensional image created from a summation
of individual digital breast tomosynthesis image slices.
Volumetric breast density Computer-calculated percentage score of dense fibroglandular tissue volume
to the overall breast volume.
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Plain English summary
B reast screening is recognised as the best way to detect early-stage breast cancer and reducethe number of deaths from this disease. In a standard breast screening radiograph (mammogram),
overlapping breast tissue may hide some cancers or make normal tissue appear abnormal.
Digital breast tomosynthesis (DBT) takes multiple low-dose radiographs of the breast that are processed
by a computer to reconstruct a DBT image. This allows abnormalities in the breast be seen more clearly
and could make it easier to see small cancers and decrease the number of ‘false alarms’. DBT images
are usually read with a standard two-dimensional (2D) mammogram. This double radiation exposure could
be avoided if a 2D mammogram could be created from DBT images.
The study compared the accuracy of reading (1) a 2D mammogram with (2) 2D mammogram with a
DBT or (3) synthetic 2D mammogram with a DBT to identify breast cancer. Data from 7061 cases were
analysed: 6021 cases from women (47–73 years) recalled after routine screening for further tests
and 1040 cases from women (40–49 years) with a family history of breast cancer attending annual
breast screening.
The results of the study indicated that the use of a combination of 2D+DBT or synthetic 2D+DBT
produces a small increase in the number of cancer cases detected and could help reduce the number
of women who are recalled for unnecessary tests, that is false alarms, which could reduce health-care
costs and patient anxiety.
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Scientific summary
Background
Although breast screening with mammography is recognised as the most effective method of detecting
early-stage breast cancer and reducing breast cancer mortality, up to 30% of cancers are not detected
by standard screening and this percentage is higher in dense breasts and in women under 50 years of age.
A major limitation of breast screening mammography is that overlapping fibroglandular tissue can decrease
the visibility of abnormalities or mimic abnormalities. As a result, some cancers are missed and there are
unnecessary recalls, assessments and psychological stress.
Women with increased breast density have an increased risk of developing breast cancer, have
lower screening programme sensitivity, and tend to have larger screen-detected and interval cancers.
This is of concern for the NHS Breast Screening Programme (NHSBSP) as it extends the programme
screening to include younger women and to offer screening mammography to women with a family
history (FH) of breast cancer.
Digital breast tomosynthesis (DBT) is a newly developed three-dimensional (3D) imaging technique that
has the potential to improve the accuracy of mammography by reducing interference from breast tissue
overlap. This facilitates differentiation between malignant and non-malignant features and could decrease
the number of false-positive recalls, associated health-care costs and patient anxiety.
The optimal role for DBT in the diagnosis and assessment of breast cancer is still uncertain. Current evidence
indicates that DBT should be used as an adjunct to two-dimensional (2D) mammography. However, the
additional radiation exposure required to obtain a standard 2D mammogram could be avoided if a synthetic
2D mammogram could be reconstructed from the images acquired from DBT imaging.
Objectives
l To compare the diagnostic accuracy of using DBT in conjunction with 2D or synthetic 2D, against
standard 2D mammography in a retrospective reading study.
l To determine if the use of DBT in conjunction with 2D or synthetic 2D improves the accuracy of
detection of (1) small or subtle breast cancers, (2) cancers in women with dense breasts, (3) cancers
presenting as soft-tissue masses and (4) cancers presenting as microcalcifications.
l To assess the performance of two automated breast density software programs against observer-based
visually assessed breast density.
l To assess the association of breast density with cancer incidence.
Study population
The study was conducted in six UK NHSBSP centres. Women (aged 47–73 years) recalled for further
assessment after routine breast screening and women (aged 40–49 years) with moderate/high of risk
of developing breast cancer who were attending annual mammography screening were recruited into
the trial after giving written informed consent.
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Intervention
All participants underwent standard two-view [mediolateral oblique (MLO) and craniocaudal (CC)]
2D mammography of both breasts and two-view (MLO and CC) DBT imaging acquired in a single
examination under the same degree of breast compression. Image-processing software generated a
synthetic 2D mammogram from the acquired 3D images.
Retrospective reading study
In an independent retrospective reading study, readers reviewed (1) 2D, (2) 2D+DBT or (3) synthetic
2D+DBT images for a case without access to original screening mammograms or prior examinations, and
readers were blinded to the outcome status of each case.
Sensitivities and specificities were calculated for each of the three reading arms, for all cases combined,
and then for subgroups by visually assessed breast density and dominant radiological feature. In addition,
sensitivity to cancers was calculated for subgroups by lesion size [invasive and ductal carcinoma in situ
(DCIS) separately] and histological grade. Sensitivity and specificity were compared between reading arms
using McNemar methods, and receiver operating characteristic (ROC) analysis was performed to compare
the diagnostic accuracy of the three reading arms (2D alone vs. 2D+DBT vs. synthetic 2D+DBT) by
calculating the area under the curve and p-values.
Results
A total of 8869 participants were recruited over a 21-month period. This data set comprised 7684 cases
recruited sequentially from assessment clinics and 1185 cases from women aged 40–49 years at moderate/
high risk of developing breast cancer (subsequently referred to as FH cases). The latter group provided
a cohort with higher breast density for subanalysis of the impact of breast density on the diagnostic
accuracy of DBT.
After exclusions, there were 7060 subjects for analysis comprising 6020 (1158 cancers) assessment cases
and 1040 (two cancers) FH cases. Reading data were available for 6928 (98%) cases by 2D only, 6960
(99%) by 2D+DBT and 6654 (94%) by synthetic 2D+DBT. The analysis included cases read in only two
arms of the study to avoid introducing bias and was repeated using only cases which were read in all
three arms. This produced identical results.
For all subjects combined, sensitivity was 87% [95% confidence interval (CI) 85% to 89%] for 2D only,
89% (95% CI 87% to 91%) for 2D+DBT and 88% (95% CI 86% to 90%) for synthetic 2D+DBT.
The difference in sensitivity between 2D and 2D+DBT was of borderline significance (p= 0.07) and
for synthetic 2D+DBT there was no significant difference (p= 0.6). Sensitivity was significantly higher for
2D+DBT than for 2D alone for invasive tumours of size 11–20mm, for women with breast density of
50% or more (p= 0.03), and for age range 50–59 years (p= 0.01). A similar increase in sensitivity
(p= 0.01) was seen for 2D+DBT in grade 2 invasive tumours (but not grade 1 or grade 3), and for lesions
in which the dominant radiological feature was a mass (p= 0.04). For synthetic 2D+DBT, there was
significantly (p= 0.006) higher sensitivity than for 2D alone in invasive cancers of size 11–20mm. Cancers
missed by 2D alone tended to be of size 11–20mm, or to have a mass as the major radiological sign,
compared with the other two reading modalities; cancers missed by 2D+DBT were less likely than the
other two reading modalities to be of grade 2 or to have density less than 50%. The borderline
improvement in cancer detection in the DBT reading arms compared with 2D alone differs from recent
prospective screening studies, but this may be as a result of differences in case selection and study design.
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Specificity was 58% (95% CI 56% to 60%) for 2D, 69% (95% CI 67% to 71%) for 2D+DBT and
71% (95% CI 69% to 73%) for synthetic 2D+DBT. Specificity was significantly higher for 2D+DBT
and for DBT+ synthetic 2D than for 2D (p< 0.001 in both cases). With ROC analysis, a significant increase
in diagnostic accuracy (p< 0.001) for 2D+DBT and synthetic 2D+DBT compared with 2D alone
was observed, most likely as a result of the marked improvement in specificity. The increases in specificity
for the DBT reading arms were observed in all subgroups of breast density and dominant radiological
feature and across all age groups (p< 0.001 in all cases). In all three reading arms, specificity tended to be
lower for microcalcifications and higher for distortion/asymmetry, and synthetic 2D+DBT was inferior to
both 2D and 2D+DBT in the detection of microcalcifications and DCIS of size 11–20mm.
The breast density substudy evaluating the performance of two automated breast density software
programs against observer-based visually assessed breast density indicated a high degree of variation
in density as scored by readers, whereas the two commercially available software packages appeared
to provide a more reliable assessment. The results confirmed the strong relationship between volumetric
density and increased risk of breast cancer that has already been reported but highlighted the need
for further research in this area to develop an accurate and reproducible method of breast density
measurement for the assessment of breast cancer risk.
Conclusions
This reading study showed that the performance of 2D with DBT was better than 2D alone in terms
of specificity, with a marginal improvement in sensitivity, and that synthetic 2D was comparable
to conventional 2D when used with DBT. Case selection bias in the study design limits extrapolation
of the results to a screening population. However, the observation that integrated 2D+DBT imaging was
equally effective across all age groups and breast densities (and in particular for women aged 50–59 years
and for breast density ≥ 50%) could be advantageous to the planned age extension of the NHSBSP
and to screening mammography of the younger cohort of FH women. In addition, the potential to reduce
false-positive recalls could also benefit both screening programmes and the screening population.
However, further research is required to evaluate the practicalities and costs of implementing 2D+DBT in
a screening setting and to undertake further comparison with 2D and synthetic 2D for different lesion
types and breast densities. Prognostic modelling on existing data sets could be used to predict the impact
on outcomes and mortality. Validated measures of breast density are required to assess personalised breast
cancer risk and screening recommendations. In addition, the performance of DBT systems from different
manufacturers needs to be evaluated.
Study registration
This trial is registered as ISRCTN73467396.
Funding
Funding for this project was provided by the National Institute for Health Research Health Technology
Assessment programme.
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Chapter 1 Introduction
Background
Breast screening with mammography is recognised as the most effective method of detecting early-stage
breast cancer and reducing breast cancer mortality. A recent meta-analysis of 11 randomised trials
concluded that there was a 20% relative risk reduction in breast cancer mortality in women invited
to screening.1 However, one of the primary limitations of standard two-dimensional (2D) mammography is
that overlapping dense fibroglandular tissue within the breast can decrease the visibility of malignant
abnormalities or simulate the appearance of an abnormality. This reduces the sensitivity of screening and
increases the number of false-positive recalls.2 It has been shown that 15–30% of cancers are not detected
by standard screening,3 and this percentage is higher in women aged under 50 years4 and in women with
dense breasts.5–7 Women with dense breasts have reduced screening programme sensitivity8–11 and tend to
have larger screen-detected and interval cancers.8,12,13 These issues are of concern for the UK NHS Breast
Screening Programme (NHSBSP) as it extends the screening age range to include younger, pre- or
perimenopausal women who are known to have a higher proportion of dense breast tissue14,15 and is also
potentially problematic for women at moderate or high risk of developing familial breast cancer who
attend annual mammography.14
Digital breast tomosynthesis
Digital breast tomosynthesis (DBT) is a newly developed three-dimensional (3D) imaging technique that
has the potential to improve the accuracy of mammography by reducing overlapping shadows from
breast tissue that degrade the image quality in standard 2D projection imaging. This should improve
the visibility of cancers and facilitate the differentiation between malignant and non-malignant features.
The expectation is that small cancers, which may be obscured by normal fibroglandular tissue in standard
2D projection imaging, could be more readily detected using DBT, particularly in women with radiologically
dense breasts. In addition, by facilitating the analysis of superimposed breast structures, DBT may
enable the reader to identify features such as asymmetrical density (ASD) on 2D imaging as normal
composite shadows and thereby decrease the number of false-positive recalls16–19 and the associated
health-care costs20 and patient anxiety.21,22
Development and process
The fundamentals of tomographic imaging were established in the 1930s, but clinical applications of
tomosynthesis in mammography did not evolve until several decades later, following the development
of flat-panel digital display detectors, rapid computer processing and advances in reconstruction and
post-processing algorithms.23 In DBT, a sequence of projection images is obtained by moving the position
of the X-ray tube and making exposures at regular intervals/angles. The angular range used varies from
one manufacturer to another. In the Hologic Selenia Dimensions System (Hologic Inc., Bedford, MA, USA)
used in this study, 11 exposures are taken over an angular range of 15 degrees. The exposure used for
each projection image is relatively small so that the overall mean glandular dose (MGD) for DBT is
comparable with that of conventional 2D imaging. The projection images acquired by the detector are
processed by reconstruction algorithms to produce a pseudo-3D tomographic image of the breast in which
each reconstructed image (or slice) shows the tissues sharply for that plane and blurs out details in higher
and lower planes. Typically, this reconstruction is done to produce images with a 1-mm slice thickness
although increased slice thickness can be used. Image quality of DBT is highly dependent on system
geometry and the choice of optimal image acquisition, reconstruction and display parameters.24–27
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Some manufacturers employ a larger angular range, which would theoretically improve the depth
resolution between planes, but at the expense of in-plane resolution.25,26 A viewing workstation provides
tools that enable the reader to scroll vertically through the tomographic images as well as to compare
them with the corresponding 2D images.
Diagnostic accuracy
The superiority of DBT over standard 2D projection imaging in terms of lesion visibility and margin detection
was first demonstrated in experimental studies using phantoms and mastectomy specimens.28–30 Improved
lesion visibility, size and classification compared with standard film or digital mammography have been
reported31–38 and the possibility that DBT could reduce the need for additional mammographic views at least
for non-calcified lesions39–42 has been suggested. There are mixed reports of the sensitivity of DBT for the
detection of microcalcifications32,43–51 that may be partly as a result of the different techniques used for
image reconstruction and the need to combine image slices into thicker slabs for optimal visualisation of
microcalcification clusters. These observations suggested that DBT was unlikely to be used as a stand-alone
imaging modality if a 2D mammogram was required for optimal microcalcification assessment.25,52,53
Cancer detection and recall rate
Higher sensitivity of DBT, either alone or in combination with 2D mammography, has been
reported16,19,45,48,54,55 although no change56 or reductions in sensitivity of between 4% and 9% were also
noted in some comparison studies of one-view and two-view DBT versus 2D or DBT added to 2D.33,44,57
Several studies have shown increased specificity of DBT compared with 2D16,33,45 and in combination with
2D mammography.16,20,43,46,58 In a multireader multicentre trial using receiver operating characteristic (ROC)
analysis, Rafferty et al.17 reported increased diagnostic accuracy of 2D+DBT compared with 2D alone,
particularly in the detection of invasive cancers, and a reduction in the false-positive recall rate and a large
retrospective evaluation of screening mammography in 13,158 women59 reported a significantly lower
recall rate with 2D+DBT compared with 2D alone, especially for women aged < 50 years and those
with dense breasts. However, the latter study was underpowered to demonstrate any significant increase
in cancer detection rate. Rose et al.60 conducted an observational study to assess changes in screening
performance measures after the introduction of DBT. Six radiologists interpreted 13,586 screening
mammography studies without DBT and 9499 studies with the addition of DBT. Routine use of 2D+DBT
resulted in a significant reduction in recall rate and, although changes in other performance measures, for
example cancer detection rate (in particular, earlier detection of invasive cancers), biopsy rate and positive
predictive value, did not reach statistical significance, this was attributed to study design limitations.
In general, published studies have demonstrated the potential for DBT to decrease recall rates and possibly
increase cancer detection rates.61,62 Some of the conflicting results and uncertainties from early studies may
be attributed to differences in study methodology, case composition and the use of prototype DBT systems
from different manufacturers with different configurations.63–65 The Houssami and Skaane review64 did
conclude that the available data did support investment of new large-scale randomised population
screening trials.
Several population-based screening trials are now in progress, although none is randomised:
Oslo Tomosynthesis Screening Trial
The Oslo Tomosynthesis Screening Trial, the first large-scale trial to implement DBT, compares various
screen-reading protocols. Interim analysis of data from 12,631 participants reported a 27% increase
in cancer detection rate across all breast densities, a significant increase (40%) in the detection of invasive
cancers and a 15% decrease in false-positive recall rate with 2D+DBT mammography compared with
2D alone.19
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Screening with Tomosynthesis OR standard Mammography trial
The results of the Italian STORM (Screening with Tomosynthesis OR standard Mammography) trial66 were
consistent with interim data from the Oslo trial. In a population-based screening programme, a significant
increase in cancer detection was observed across all age groups and breast densities comparing sequential
2D screen reading and combined 2D+DBT. In addition, the study showed that 2D+DBT had the potential
to reduce the false-positive recall rate by 17%.
Malmö Breast Tomosynthesis Screening Trial
The Malmö Breast Tomosynthesis Screening Trial (https://clinicaltrials.gov/ct2/show/NCT01091545)
is conducting a paired analysis of the sensitivity and specificity of DBT compared with 2D in a
population-based screening programme in Sweden. Preliminary results indicated a 15% increase
in sensitivity with DBT compared with 2D mammography but with a slight (3%) increase in recall rates.
These screening studies provide the best evidence available to date that the combined use of DBT
and 2D may increase the number of cancers detected, with a large impact on decreasing the number
of unnecessary recalls.
Reader performance
The need for substantial reader training with DBT has been acknowledged.16,67,68 Multireader studies
have demonstrated improved performance, using DBT in combination with 2D mammography compared
with 2D mammography alone, by radiologists with a range of experience, as measured by reduction in
recall rate and ROC analysis.17,58,69 However, Wallis et al.,46 using a photon-counting DBT system, reported
that the addition of DBT improved the performance only of inexperienced readers. Reading and reporting
times are considerably longer (almost twofold) using DBT,16,46,68,70 with a reading time of 91 seconds for
2D+DBT compared with 45 seconds for 2D alone in a screen-reading setting19 because of the number of
images to be reviewed. This has resource implications if DBT were to be introduced into screening practice,
although the impact on workflow could be mitigated if recall rates were shown to be decreased and
unnecessary diagnostic assessments avoided.71
A number of publications have summarised and reviewed both the technical and the clinical aspects
of DBT and have speculated on its potential application in breast imaging.23,25–27,61,63,64,72,73 The AETNA
policy report,74 a combined recommendation from the American College of Radiologists, the American
Cancer Society and the American College of Obstetrics and Gynaecologists, considers that breast
tomosynthesis imaging is experimental and investigational because of insufficient evidence of its
effectiveness. An Australian health technology review acknowledged that DBT systems were likely to
replace 2D in screening when existing 2D equipment is due for replacement75 and an overview of the
evidence and issues to be considered in relation DBT and breast cancer screening raised concerns
regarding additional radiation exposure and the learning curve for radiologists to accurately interpret
DBT results.65
The use of DBT in combination with 2D requires an approximate doubling of radiation exposure.
Hologic have developed image-processing software [C-View™ (Hologic Inc., MA, USA, 2011)] to simulate
a conventional 2D mammogram by generating a synthetic 2D image from each set of tomosynthesis
slices,70,76 thus eliminating the need for the acquisition of additional 2D exposures. One published study70
has reported lower sensitivity using synthetic 2D+DBT than using 2D+DBT but the authors
acknowledged that greater diagnostic accuracy may be achieved with newer versions of the software.
Synthetic 2D is currently being evaluated within the Oslo trial.77,78
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Rationale for study
The need for robust studies using clinically relevant methodology to further inform the optimal role,
if any, for DBT in the diagnosis and assessment of breast cancer has been highlighted.63–65,79 Of primary
importance is further research to address whether DBT should be used as an adjunct to standard 2D
or as a stand-alone technology.
To assist in the choice of DBT system to be used in the study, a working party was set up at the start
of the project in 2010 by some of the grant applicants to review the status of DBT system technology.
When the working party report was published,80 seven companies were involved in the development
of commercial DBT systems, and the group concluded that a multivendor evaluation of DBT systems
in the study would be premature at this stage, as some of vendors’ DBT technology was still being
developed. The Hologic DBT system was relatively well established, was technically stable and was the
only commercially available system with US Food and Drug Administration (FDA) approval at the start of
the trial. The Hologic DBT system allows both 2D and DBT images to be acquired in a single examination
with the same breast position and compression (combination mode), enabling direct comparison of the
performance of the two imaging modalities. This reduces any bias that could occur as a result of different
positioning of the breast when taking the second image. The rapid acquisition time (< 10 seconds)
minimises patient discomfort and patient movement, which could result in blurring of the acquired images,
and a fast image-processing time (3–4 seconds) minimises the impact on clinic workflow. In addition, the
system coregisters the 2D and DBT images, thus facilitating image interpretation and lesion localisation.
Research objectives
The purpose of the study was to test the diagnostic accuracy of DBT as an adjunct to standard 2D
mammography as a primary screening tool.
Primary objectives
l To compare the diagnostic accuracy of using DBT with 2D, and DBT with synthetic 2D, with standard
2D in women aged 47–73 years.
l To determine if the addition of DBT to 2D or synthetic 2D improves the accuracy of detection of small
or subtle breast cancers.
l To determine if diagnostic accuracy improves in women with dense breasts by using DBT with 2D.
Secondary objectives
l To compare the diagnostic accuracy of DBT with 2D, and DBT with synthetic 2D, against standard
2D in:
¢ women aged 40–49 years with a moderate or high risk of breast cancer as a result of family history
(FH) and who attend annual screening mammography
¢ cancers presenting as soft-tissue masses
¢ cancers presenting as microcalcifications.
l To assess the performance of two automated breast density software programs against observer-based
visually assessed breast density.
l To assess the relationship of breast density with cancer incidence.
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Chapter 2 Methodology
Study design
This study is a multicentre retrospective reading study comparing the diagnostic performance of 2D+DBT
versus 2D and synthetic 2D+DBT versus 2D. The overall study design is shown in Figures 1 and 2.
Two-view 2D and two-view DBT imaging in a single procedure
at the same breast compression
Image files stored locally
2D and DBT images reviewed by reader(s) at site
Prospective evaluation of images from
assessment clinic cases
Reader reviews both screening and
assessment images. Records suspicion 
(1–5 scale), lesion conspicuity (1–5 scale),
location and type of any abnormality. Also
makes assessment of DBT vs. 2D and a
visual assessment of breast density (0–100%)
Local data manager copies 2D and DBT images for each case and anonymises
images prior to sending via secure transfer to trial office 
Trial office team check data integrity of anonymised case files
from each centre, log cases in database and store collated data
Radiographers check images from 10% of all normal cases and
all cancer cases against received data 
Patient information sheet and consent form
sent to high/medium risk women (owing to
their FH) with their invitation to attend
 screening mammography    
Prospective evaluation of images from
screening mammography
Two readers independently review screening
images and any previous films. Record
recall/no recall opinion; suspicion (1–5 scale),
lesion conspicuity (1–5 scale), location and 
type of any abnormality. Also make
assessment of DBT vs. 2D and a visual
assessment of breast density (0–100%)
Patient information sheet and consent form
sent to women who had been recalled to
assessment clinic for a suspected abnormality
on screening mammography   
Written informed consent at clinic; trial ID allocated
FIGURE 1 Case collection.
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Study settings and population
Participants were recruited from six NHSBSP centres in the UK and from the symptomatic breast service
in Aberdeen. They comprised women aged 47–73 years recalled to an assessment clinic for a
mammographic abnormality detected at routine breast screening and also women below 50 years of age
with a FH of breast cancer who attended annual mammography screening.81 The purpose of targeting this
group of women was to compile a data set with a relatively high proportion of cancer cases (estimated to
be approximately 18%). It was expected there would be around 50% of cases with overlapping tissues on
standard 2D mammography that simulated suspicious features but were actually normal breast tissue.
Recruitment
A participant information leaflet (see Appendices 1 and 2) outlining the potential benefits and risks
of the study was sent to women who would be suitable for inclusion in the study, and written
informed consent (see Appendix 3) was obtained on attendance at the assessment clinic or screening
mammography appointment.
Randomisation of cases to readers at six sites for independent blinded review
Each case is randomised to be read in three arms of the study and to be read by a different
reader in each arm:  
• 2D images alone
• 2D + DBT images and
• synthetic 2D + 3D images
Retrospective assessment in three reading arms 
2D-only arm: reader records suspicion score (1–5 scale), location, recall/no recall decision
DBT arms: in addition to those for 2D-only arm, reader also makes an assessment of 
                  2D vs. DBT for lesion visibility, extent and discrimination (1–5 scale for each)
                  An overall score for 2D vs. DBT (1–5 scale) is also recorded  
Data collection forms returned to trial office for analysis and archiving
2D and DBT images distributed to allocated readers/sites
Data manager at site prepares lists to be read on workstation
2D only Synthetic 2D + DBT2D + DBT
FIGURE 2 Reading study.
METHODOLOGY
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Inclusion criteria
l Women aged 47–73 years attending routine breast screening (either film or digital mammography)
and recalled for further assessment.
l Women aged 40–49 years with FH of breast cancer and invited to attend annual breast
screening mammography.
l Women who have had a previous diagnosis of breast cancer attending screening.
Exclusion criteria
l Any woman unable to give informed consent, including anyone unable to understand the nature
and purpose of the study.
l Any woman with breast implants.
l Any woman who was pregnant.
Intervention
All participants underwent standard two-view [mediolateral oblique (MLO) and craniocaudal (CC)]
DBT imaging and two-view (MLO and CC) 2D mammography of both breasts. For participants recruited
in assessment clinics, imaging was conducted prior to any additional investigations deemed necessary in
the assessment clinic. Following DBT and 2D imaging, women resumed the normal pathway through the
assessment or screening clinic. The DBT images were available for management of the women during
the clinic or shortly afterwards. Any subsequent management followed standard assessment clinic or
screening centre procedures.
Image acquisition
Both the DBT and the standard 2D imaging were performed as a single procedure at the same breast
compression on a Hologic Selenia Dimensions Digital Mammography Unit (Hologic Inc., Bedford, MA,
USA). This important feature of the system eliminated any bias that could have occurred as a result
of different positioning of the breast when taking the second image. Differences in compression
could significantly influence the detectability of cancers as a result of the resulting differences in the
superimposition of tissues. The rapid acquisition sequence also minimises patient discomfort and patient
movement, which could result in blurring of the acquired image. Radiographers were experienced
specialist mammography radiographers, fully trained in accordance with NHSBSP standards, who had
received additional specific training on the DBT equipment used in the study.
Radiation dose
The radiation dose for DBT was additional to normal procedures and some of the dose from the 2D imaging
may have been additional if local protocol was to take fewer initial images at assessment (some of this dose
may have been offset by not having to acquire supplementary, coned or magnification images).
The additional lifetime risk of inducing a breast cancer as a result of a single two-view mammography
examination is estimated to be approximately 1 in 20,000 between the ages of 50 and 70 years.82,83
For this trial, the total MGD was estimated at 7mGy (Table 1), giving rise to an estimated
1 in 10,000 risk of cancer induction (assuming an induction rate of 14 per million per mGy). In practice,
some of this dose would have been received during normal assessment procedures (estimated at 1.5 to
3.0 mGy depending on local practice); therefore the additional dose ranged from 4.0 to 5.5mGy. The total
dose for the trial falls just within the diagnostic reference level for standard two-view 2D mammography.
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Some of the trial participants were women aged 40–49 years with FH of breast cancer who were
attending annual surveillance mammography.81 The radiation risk implications of cancer screening in this
cohort was reviewed, with benefits expected to substantially exceed risks down to at least the age of 40.82
In the trial, the total dose including DBT was approximately 7mGy. Overall, the additional radiation dose
involved was very low and within the range currently accepted for routine screening.
Reader experience
Readers from each participating centre were a mixture of radiologists, advanced practitioner radiographers
and breast clinicians, representative of current reading practice in the NHSBSP. All readers had a proven
track record of film reading in the NHSBSP, including:
l mammographic film reading for a minimum of 2 years
l reading a minimum of 5000 mammograms per annum
l annual participation in PERsonal PerFORmance in Mammographic Screening (PERFORMS)
self-assessment test
l attendance at assessment clinics and multidisciplinary team meetings.
Readers who are indicated in Table 2 with a superscript ‘a’ contributed only to prospective reading and did
not participate in the retrospective reading study.
The number of readers available varied from week to week owing to other commitments, annual leave,
etc.; the average number per week was 16.
Prior to the start of the trial, reader training consisted of 2 days of applications training from the DBT
system manufacturer (Hologic Inc.) and attendance at a 1-day DBT reading course presented by staff
from Breast Radiology at King’s College Hospital, London. Readers were also asked to read a test set of
80 cases. These same cases were read again at the end of the trial in order to evaluate improvement in
reader performance over time. An account of this evaluation is given later in this report (see Chapter 3).
Over the first 12 months of the study recruitment period readers also gained experience of DBT by
reviewing 2D and DBT images acquired at their own site. All readers used Hologic SecurView DW
workstations (Hologic Inc., Bedford, MA), optimised to read both 2D and DBT images.
TABLE 1 Radiation dose for study
Procedure
Estimated MGD for typical breast
(50 to 60mm thick) Diagnostic reference levela
Two-view 2D 3mGy 7mGy
Two-view DBT 4mGy Not available
Total study dose 7mGy Not applicable
a Diagnostic reference level is 3.5mGy for one oblique view; this has been doubled for two views.
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TABLE 2 Summary of reader experience
Site name Reader code Reader typea
Number of
years reading
mammograms
Number of
mammograms
per year
Number of years
reading digital
mammograms
Aberdeen A3 1 11 6000 5
Aberdeen A4 1 4 6000 4
Aberdeen A1a 1 6 7000 2
Aberdeen Axa 1 15 6000 4
Aberdeen A2 1 17 6000 4
Barts B5 1 3 10,000 3
Barts B3a 1 15 8000 12
Barts B4 1 4 10,000 4
Barts B1 1 4 8000 4
Barts B2a 2 8 5147 8
Glasgow G5 1 18 12,000 2
Glasgow G3 2 10 10,000 1
Glasgow G1 1 25 5000 5
Glasgow G4 2 7 13,000 1
Glasgow G2 1 10 6000 3
Guildford J4 1 3.5 6000 3
Guildford J2 1 10 7000 2
Guildford J1 1 20 8000 3
Guildford J5 3 7 10,000 2
Guildford J3 1 18 10,000 1
Manchester M5 1 17 9000 7
Manchester M1 1 5 7000 5
Manchester M3 1 22 7000 2
Manchester M2 1 24 10,000 7
Manchester M6 3 6 7000 6
King’s College K1 1 25 13,994 2
King’s College K3a 1 8 6549 2
King’s College K4 1 6 8430 2
King’s College K6 1 23 8061 2
King’s College K7 1 3 8525 2
King’s College K8 2 10 8000 2
a Reader type 1= consultant radiologist; 2= advanced practitioner radiographer; and 3= breast physician.
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Image management
Images acquired on the Hologic Selenia Dimensions system were exported to a number of output devices:
l SecurView DX workstation (Hologic Inc, Bedford, MA, USA): Processed 2D and DBT image files were
exported to the workstation for review by readers.
l Picture archiving and communications system (PACS): Processed image files that formed part of a
patient’s screening episode were exported to PACS. Individual centres determined whether or not to
store the processed DBT image files on their NHS PACS system. Archiving was initiated following
processing of all images collected for the study.
l Hologic SecurXchange (Hologic Inc, Bedford, MA, USA)/Hologic Image Collection System (HICS)
(Hologic Inc, Bedford, MA, USA): An output set containing both the raw and the processed DBT and
2D image files was exported to the SecurXchange archiver unit and HICS for anonymising and storage
prior to image transfer to the trial office.
Anonymisation of images
Copies of the 2D and DBT image files for each participant were anonymised prior to transfer to the
trial office. A program in the HICS removed patient-identifiable data from the Digital Imaging and
Communication in Medicine (DICOM) files. Two output files were generated for each case. The first
contained identifiable patient data and a site-specific R2 number and provided the master link between
anonymised and identifiable data. The second file was generated by the HICS after the anonymisation
process and contained only a list of dates and R2 numbers. Images transferred to the trial office via the
Hologic SecurXchange unit were identified by R2 number and R2 ID only.
Image storage at trial office
Images from each site were collated and stored in the Central Data Repository (CDR) on the University
of Cambridge network server in readiness for copying and distribution to sites for the retrospective reading
study. A detailed report on image management can be found in Appendix 4 together with a diagram
representing flow of data (see Appendix 5, Figure 29).
Digital breast tomosynthesis quality control
All DBT systems used in the study were tested prior to the start of the trial by the National Co-ordinating
Centre for the Physics of Mammography (NCCPM) to ensure that the 2D imaging performance met
the minimum standards required by the NHSBSP and to establish baseline DBT and 2D performance.84
Each system was also tested by physicists on installation, prior to clinical use, and every 6 months for
the duration of the trial. Physicists from NCCPM worked with the local physics service at each participating
centre to establish quality control (QC) procedures. Full details of QC testing are reported in Appendix 6.
In addition, standardised routine QC tests on workstations were undertaken by radiographic staff on
a weekly basis in accordance with manufacturer’s guidelines.
Prospective data collection
The purpose of this was to create a ground truth database as a reference for the reading study by
collecting detailed information on each case recruited. The database collated data from prospective
reading and histopathology reports.
Review of images from assessment clinic cases
The 2D and DBT images were reviewed in the assessment clinic by one reader and used to inform
subsequent patient management. Data were collected prospectively for each case using proforma data
collection sheets (see Appendix 7). Where a case had multiple lesions, a separate sheet was used for each.
METHODOLOGY
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For each case, the position of any lesion seen in the breast was marked with an X on a grid consisting
of nine squares. Suspicion was scored on a standard five-point scale.85 Lesion type (0–5 scale) and lesion
conspicuity (0–3 scale) were also recorded. Readers were also asked to give their opinion on the overall
performance of 2D versus DBT on a –2 to +2 preference scale and comment on any additional information
obtained from the DBT images. They also recorded an assessment of breast density on a 10-cm visual
analogue scale (VAS). The outcome of the assessment was recorded.
Review of images from high-/moderate-risk screening mammography cases
The DBT and 2D images were reviewed by two readers as independently and data recorded on proforma
data collection sheets (see Appendix 8).
Each reader reviewed the DBT and 2D images and, for each case, the position of any lesion seen in
the breast was marked with an X on a grid consisting of nine squares. Suspicion was scored on a
standard five-point scale.85 Lesion type (0–5 scale) and lesion conspicuity (0–3 scale) were also recorded.
Readers were also asked to give their opinion on the overall performance of DBT versus 2D on a –2 to
+2 preference scale and comment on any additional information obtained from the DBT images. They
also recorded an assessment of breast density on a 10-cm VAS. An overall decision of recall/no recall
was recorded.
Assessment of breast density
Qualitative or quantitative measurement of breast density from 2D mammograms is known to be highly
subjective and variable.86 DBT has the potential to enable direct measurement of volumetric radiological
density.87 Each reader recorded a rating of breast density on a 10-cm VAS from the DBT and 2D images
for each case. These were converted into percentages and compared with the automated breast density
calculated using Quantra™ Version 2.0 (Hologic Inc., Bedford, MA, USA) and Volpara™ Version 1.4.2
(Matakina Technology Limited, Wellington, New Zealand) software packages. The methods and findings
from these comparisons are described later in this report (see Chapter 4).
Histopathology data
Histopathology from core biopsy or surgical excision was used as the gold standard to confirm the
presence of a cancer. The outcome of assessment procedures, for example core biopsy and/or surgical
excision, was collected at each site (see Appendix 9) and collated with the reading data for each case
to generate a ground truth database.
Prospective data checks
Detailed logic checks were undertaken of all prospective assessment data, particularly in cases where
there was a discrepancy between the initial assessment data and the final histology data, to ensure that
all cancer cases were identified. The majority of cases that had initially been scored as suspicious
of malignancy were subsequently scored as benign based on the DBT images or review of prior images
from other centres, or after ultrasound examination had been performed.
In addition, the FH prospective data were thoroughly checked for data accuracy and the principal
investigator (PI) at each site was asked to confirm that all cancer pathology data had been sent
to the trial office.
Retrospective reading study
Study data set
Images and prospective data collection information, clinical outcome and histopathology data were
collated into a ground truth database from which cases could be identified to distribute to centres for the
retrospective reading study.
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Reading arms
It has not yet been determined whether or not DBT could be used as a stand-alone imaging modality for
breast screening or whether or not it should be used in addition to 2D. Since there is some uncertainty
over the visibility of microcalcification clusters,17,43,44,48,49,51 it has been suggested that a standard 2D
mammogram may be required along with two-view DBT for optimal microcalcification assessment.16,25,47,53,88
However, concerns have been raised regarding the additional radiation dose this would involve.
Software has become available that creates a synthetic 2D image from a single DBT scan, simulating
a conventional 2D image. The combination of DBT with 2D requires approximately doubling the radiation
dose to the breast being imaged. If it can be demonstrated that synthetic 2D images are satisfactory
and comparable to 2D (in combination with DBT), double exposure could potentially be eliminated.
Therefore, in this study the diagnostic performance of three imaging regimens were compared:
(a) two-view 2D
(b) two-view 2D+ two-view DBT
(c) two-view synthetic 2D+ two-view DBT.
Synthetic two-dimensional images
Two separate batches of DBT images were exported from the repository at the University of Cambridge
onto portable encrypted hard drives. These were sent to Hologic Inc. for production of synthetic 2D images
using conversion software. On return, all images were uploaded into the repository. For logistical reasons,
images from some cases were not sent for conversion.
Randomisation process and distribution of images to readers
Cases were randomly selected from the study data set to be distributed between readers and centres
to minimise bias. Only cases with a complete set of images, that is left and right MLO and left and right
CC, were included in the retrospective study. The only exceptions to this were women who had
undergone mastectomy. Each reading set comprised approximately 40 cases per reader per week, and
consisted of a mix of normal, benign and cancer cases.
Cases were randomised using a program called R, version 2.15.1 (R Foundation for Statistical Computing,
Vienna, Austria) (see Appendix 10). This program was managed by Cambridge Clinical Trials Unit. The tool
required a list of reader IDs, capacity to be allocated to individual readers and a list of anonymised case
IDs, selected from the study data set, as an input file. It allocated cases with a logic that the recruiting site
and the sites in which each of the three arms were read were always different. A text file was generated
by the program listing cases for each reader.
Retrospective data collection
Image review
Readers reviewed (1) 2D images or (2) 2D+DBT or (3) synthetic 2D+DBT images for any one case
and did not review any cases from their own centre. Cases were read on a workstation without access
to the original screening mammograms or prior examinations. Readers were blinded to the outcome status
of each case and read cases independently of all other readers.
For the 2D-only arm, the location of any suspicious abnormality in the breast was recorded on a nine-square
grid on the data collection proforma (see Appendix 11). Suspicion was scored on a five-point scale85 and a
decision to recall or not was recorded.
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For both DBT arms, slice numbers where the lesion was best demonstrated were also recorded.
Lesion visibility, lesion extent, discrimination and an overall opinion of DBT versus 2D were all scored
on a preference scale from – 2 to + 2. Readers also recorded a decision to recall or not recall based on
(1) 2D images alone, (2) DBT images alone and (3) 2D+DBT images combined for each case
(see Appendix 12).
Collation and cleaning of data
The retrospective study data were collated into a database designed using MACRO v4.2.2.3810
(InferMed, London, UK). Data collected on the retrospective proforma sheets were input by the trial team
at Cambridge. The trial data manager checked for missing and erroneous data using query management
in MACRO. Further checks were carried out by research radiographers. Data queries were relayed back
to originating sites and the response recorded. An initial database lock was performed to check the
completeness of the data and the download was sent to the statistician for analysis. All queries from
the statistician were resolved before the final data analysis was done.
Retrospective data checks
All cases for which a reader recorded a high level of suspicion that was not reflected in the recall data
(i.e. the case was marked as ‘No Recall’) were returned to the reader to confirm accuracy of data. Similarly,
cases for which suspicion was low but which were recorded as ‘Recall’ were returned to reader
for clarification.
Statistics and analyses
Sample size
The power calculations assumed that, for any given cancer case, at least one of the reading arms gave
the ‘correct’ answer (malignant or not). This was generally conservative. Assuming that some cancer cases
will have been wrongly classified by all three reading arms, this would tend to reduce the number
of discordant observations but would increase the absolute difference within the discordant observations.
The latter tends to outweigh the former in terms of power. For the main study, we wished to compare 2D
mammography with 2D+DBT and synthetic 2D+DBT to detect as statistically significant any improvement
of sensitivity or specificity conferred by either of the DBT combinations. In particular, we wanted
to determine if the addition of DBT to 2D or synthetic 2D improves the accuracy of detection of small
or subtle cancers and in women with dense breasts.
We also wanted to examine whether or not the addition of DBT could prove to be particularly useful
for a number of subgroups:
l women aged 40–49 years with moderate or high risk of familial breast cancer
l cancers presenting as soft-tissue masses
l cancers presenting as microcalcifications.
The sample size calculation was powered to allow statistically significant differences to be evaluated
for subgroup analyses.
Sensitivity
The smallest expected subgroup of cancers is likely to be around 15% of the total tumour population.
In any given subgroup, we postulated a sensitivity for 2D mammography of 85% and for 2D+DBT of
95%. Assuming that both detect a cancer in 80% of cases, that is discordance between the two imaging
modalities of 20%, we would expect the percentages seen in Table 3 to be observed.
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With a 5% significance level and two-sided testing, to have 90% power to detect the above difference
(5% missed by DBT and 15% missed by 2D) as significant requires at least 38 cancers with discordant
findings.89 Thus, 190 cancers (38/0.2) were needed in the subgroup. As stated above, the smallest
subgroup was likely to be approximately 15% of the total; therefore, a total of 1267 cancer cases was
required. Approximately 18% of cases recalled for assessment are ultimately found to have breast cancer.
This implies a total study size of 7000 assessment cases. A study population of this size would have at least
90% power for any subgroup that is at least 15% of the total study and 80% for any subgroup that is
at least 11%. We expected that the difference between 2D and 2D+DBT would be larger than that
between 2D and DBT alone, and, therefore, these comparisons would also be sufficiently powered.
Specificity
It might be reasonable to anticipate that the specificity of 2D would be 93% and that the addition of DBT
might improve this to 97%. Assuming 90% agreement between the two imaging modalities, negative
assessment outcomes would be as shown in Table 4.
For 90% power to detect this as significant, we required 62 discordant negative cases in any given
subgroup, that is 620 negative cases in total in any given subgroup. Since the subgroups of interest were
all expected to be at least 15% of the total study size, we expected 1050 (15% of 7000) subjects in each
subgroup, of whom 861 (82%) would be negative. Thus, there will be > 90% power for the postulated
difference in specificity. Again, larger differences between 2D and 2D+DBT would be expected, so these
are also sufficiently powered.
TABLE 4 Potential differential specificity; anticipated percentage of non-cancers ruled out by each
imaging modality
Ruled out by 2D+DBT
Ruled out by 2D mammography
No (%) Yes (%) Total (%)
No 0 3 3
Yes 7 90 97
Total 7 93 100
TABLE 3 Potential differential sensitivity of 2D and 2D+DBT; anticipated percentage distribution of cancers
identified by each imaging modality
Detected by 2D+DBT
Detected by 2D mammography
No (%) Yes (%) Total (%)
No 0 5 5
Yes 15 80 95
Total 15 85 100
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Analysis
Sensitivities and specificities were calculated for each of the three reading arms, firstly for all cases
combined, and then for subgroups by breast density and dominant radiological feature. In addition,
sensitivity to cancers was calculated for subgroups by size [invasive and ductal carcinoma in situ (DCIS)
separately] and histological grade. In view of the matched nature of the data (i.e. that each imaging
modality is applied to the same cases), analysis of binary outcomes (e.g. presence or absence of a specific
feature) was by McNemar methods.90 This implied that, for a comparison of two imaging modalities, only
cases with non-missing data for each modality were included. Typical data for such analysis can be
tabulated as in Table 5.
The formal comparison of sensitivity of the two imaging modalities depends only on the discordant
observations b, cancers seen only on 2D, and c, cancers seen only on DBT. If both are equally sensitive,
b and c will be approximately equal, that is one modality misses as many cases as the other, although not
necessarily the same individual cases. If DBT has superior sensitivity, c will tend to be larger than b.
The McNemar inference depends on the difference between these two discordant totals, b and c.
A similar comparison of discordant totals among the subjects with a non-cancer outcome of the complete
assessment episode was made to assess the significance of the difference in specificities.
The outcomes from the three arms of the reading study were compared with the gold standard of the final
histopathological verification of the presence of benign or malignant disease. If a woman was returned
to routine screening this was deemed a normal case.
In addition to calculation of sensitivities and specificities for histologically diagnosed cancer, we also
estimated and compared ROC curves based on the five-point suspicion score of the radiologists for each
imaging modality. As a single measure of accuracy, we used the area under the ROC curve (AUC).
Significance testing and calculation of 95% confidence intervals (CIs) on the AUCs were performed
using the method of De Long et al.91 Statistical analysis was performed using Stata version 10.0
(Stata Corporation, College Station, TX, USA).
TABLE 5 Cancers diagnosed at assessment tabulated by detection method
Detected by 2D+DBT
Detected by 2D mammography
No Yes Total
No a b a+ b
Yes c d c+ d
Total a+ c b+ d a+ b+ c+ d
a, cancers that were not seen in the reading study by either DBT or 2D; b, cancers seen only on 2D, not on DBT; c, cancers
seen only on DBT; d, cancers seen on both 2D and DBT.
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Chapter 3 Reader study
Introduction
Digital breast tomosynthesis is a relatively new imaging modality, and few readers have extensive
experience of it in a screening setting. This study aimed to establish whether or not increased experience
of reading DBT images, as measured at the start and end of the TOMMY trial (a comparison of
TOMosynthesis with digital MammographY in the UK NHS Breast Screening Programme), altered
performance in terms of recall rate and cancer detection. This knowledge is important when designing
training regimes for new readers.
Aims
The specific aims of the reader study were:
1. to investigate variability in performance of readers involved in the TOMMY trial
2. to determine if there was a change in individual performance over the course of the trial
3. to determine if performance is related to prior experience with DBT or digital mammography
4. to determine if change in performance over the course of the trial is related to the number of DBT
images read during the trial
5. to determine whether or not change in performance during the course of the trial is related
to previous experience.
Method
In total, 80 DBT cases were identified from those obtained prior to the TOMMY trial at King’s College
Hospital in London. Of these, 39 cases contained either no abnormality or benign abnormalities, while
41 cases contained a cancer. Ground truth was provided, with cases classified as normal, benign,
malignant in situ or malignant invasive (Table 6).
Twenty-eight readers from TOMMY trial sites assessed the set of 80 DBT cases, completing a proforma
for every lesion identified. Of these, 22 of the readers assessed the image set on two occasions, before
the start of the trial and at the end of it. Results are presented for those readers who completed both
reads (Table 7). The order in which the cases were assessed was randomised for each read.
For these results we have focused on the suspicion score allocated to each case (Table 8).
TABLE 6 Test set by case type
Case type Number of cases
Normal 7
Benign 32
Malignant (in situ) 15
Malignant (invasive) 26
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TABLE 7 Recall rates based on a suspicion score of 3 or more
Reader
study ID
T1 T2 Δ (T2 – T1)
Proportion
of cancer
cases
recalled
Proportion of
normal/benign
cases not
recalled
Proportion
of cancer
cases
recalled
Proportion of
normal/benign
cases not
recalled
Proportion
of cancer
cases
recalled
Proportion of
normal/benign
cases not
recalled
R2 0.98 0.64 0.85 0.62 –0.12 –0.03
R3 1.00 0.18 0.95 0.44 –0.05 0.26
R4 0.80 0.56 0.83 0.63 0.02 0.07
R6 0.95 0.54 0.90 0.46 –0.05 –0.08
R7 0.93 0.33 0.93 0.38 0.00 0.05
R10 0.93 0.67 0.93 0.62 0.00 –0.05
R13 0.95 0.26 0.95 0.26 0.00 0.00
R14 0.95 0.54 1.00 0.35 0.05 –0.19
R15 0.95 0.21 0.98 0.54 0.02 0.33
R16 0.93 0.51 0.93 0.49 0.00 –0.03
R17 0.93 0.51 0.95 0.46 0.02 –0.05
R18 1.00 0.08 1.00 0.31 0.00 0.23
R19 1.00 0.18 0.95 0.45 –0.05 0.27
R20 1.00 0.18 1.00 0.46 0.00 0.28
R21 1.00 0.21 0.95 0.38 –0.05 0.18
R22 1.00 0.18 1.00 0.21 0.00 0.03
R23 0.98 0.28 1.00 0.51 0.02 0.23
R24 0.90 0.56 0.93 0.49 0.02 –0.08
R25 0.93 0.54 0.95 0.53 0.02 –0.01
R26 0.98 0.15 0.95 0.25 –0.02 0.10
R27 1.00 0.44 1.00 0.16 0.00 –0.28
R28 0.95 0.44 0.98 0.26 0.02 –0.18
All readers 0.96 0.37 0.95 0.42 0.01 0.01
T1, time point 1; T2, time point 2.
TABLE 8 Suspicion classification (based on Maxwell et al.85)
Classificaton Suspicion
1 Normal
2 Benign
3 Probably benign (recall)
4 Suspicion (recall)
5 Malignant (recall)
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Results
The results are shown in Table 7. A recall corresponded to a suspicion score of 3 or more. The proportion
of cancer cases correctly recalled ranged from 0.80 to 1.00 at the first time point and from 0.83 to 1.00
at the second time point. The proportion of normal/benign cases not recalled ranged from 0.08 to 0.67 at
the first time point and from 0.16 to 0.63 at the second time point. However, the number of cases
that were actually normal was very low (7 out of 80 cases) so we would expect a significant recall rate
for normal/benign cases. There was no significant difference between the recall rates before and after the
trial (p= 0.501 cancer, p= 0.198 normal/benign).
Table 9 shows the results with a higher threshold on the suspicion score. The proportion of cancer cases
correctly identified as suspicious or malignant ranged from 0.61 to 0.88 at the first time point and from
0.61 to 0.95 at second time point. The proportion of normal/benign cases scored normal, benign or
TABLE 9 Proportion of cancer cases identified as suspicious or malignant, and the proportion of normal/benign
cases scored normal, benign or probably benign
Reader
study ID
T1 T2 Δ (T2 – T1)
Proportion
of cancer
cases scored
4 or 5
Proportion of
normal/benign
cases scored
1 to 3
Proportion
of cancer
cases scored
4 or 5
Proportion of
normal/benign
cases scored
1 to 3
Proportion
of cancer
cases scored
4 or 5
Proportion of
normal/benign
cases scored
1 to 3
R2 0.71 0.90 0.61 0.87 –0.10 –0.03
R3 0.80 0.82 0.66 0.90 –0.15 0.08
R4 0.63 0.97 0.66 0.95 0.02 –0.03
R6 0.66 0.95 0.68 0.92 0.02 –0.03
R7 0.76 0.87 0.76 0.82 0.00 –0.05
R10 0.71 0.85 0.76 0.87 0.05 0.03
R13 0.73 0.82 0.80 0.62 0.07 –0.21
R14 0.61 0.92 0.68 0.97 0.07 0.05
R15 0.88 0.64 0.88 0.74 0.00 0.10
R16 0.80 0.89 0.76 0.79 –0.04 –0.10
R17 0.71 0.85 0.76 0.82 0.05 –0.03
R18 0.76 0.87 0.95 0.67 0.19 –0.21
R19 0.68 0.95 0.68 0.79 0.00 –0.15
R20 0.83 0.74 0.80 0.82 –0.02 0.08
R21 0.83 0.82 0.80 0.87 –0.02 0.05
R22 0.85 0.74 0.88 0.77 0.02 0.03
R23 0.83 0.82 0.78 0.90 –0.05 0.08
R24 0.71 0.85 0.66 0.92 –0.05 0.08
R25 0.71 0.85 0.76 0.77 0.05 –0.08
R26 0.88 0.62 0.90 0.69 0.02 0.08
R27 0.83 0.77 0.93 0.63 0.10 –0.14
R28 0.71 0.87 0.71 0.85 0.00 –0.03
All readers 0.75 0.84 0.77 0.82 0.03 –0.03
T1, time point 1; T2, time point 2.
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probably benign ranged from 0.62 to 1.00 at the first time point and from 0.62 to 0.97 at the second time
point. Once again there was no significant difference between time points (p= 0.470 and p= 0.339,
respectively). Data from Tables 7 and 9 are plotted in Figures 3 and 4, respectively.
Tables 10–12 show the results ranked by reader experience. Table 10 shows the change in performance
between reads ranked according to the volume of DBT undertaken within the trial between the two time
points. Table 11 shows the change in performance ranked according to full-field digital mammography
(FFDM) experience (number of mammograms read) in the 12 months prior to the trial and Table 12 shows
the baseline performance ranked by FFDM experience based on the number of mammograms read during
the year. Table 13 shows the results ranked by number of years reading mammograms and Tables 14
and 15 show the analysis by site. Figure 4 shows performance at the initial read by FFDM load in the
previous 12 months and Figure 5 by number of years reading mammograms prior to the study. Figures 6,
7 and 8 illustrate performance by site at the two time points.
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FIGURE 3 Proportion of cancer cases recalled, plotted against the proportion of normal/benign cases not recalled
at time point 1 (♦) and time point 2 (█ ).
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FIGURE 4 Proportion of cancer cases identified as suspicious or malignant, and the proportion of normal/benign
cases scored normal, benign or probably benign at time point 1 (♦) and time point 2 (█ ).
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TABLE 10 Change in performance between the two reads ranked according to the number of DBT reads
undertaken between the two time points. Experience of digital mammography film reading in the 12 months
prior to the first read is also presented
Reader
study ID
Number of
digital DBT
reads
Number of
DBT reads
between
the two
time points
Proportion of
cancer cases
recalled
Proportion of
cancer cases
scored 4 or 5
Proportion of
normal/benign
cases not
recalled
Proportion of
normal/benign
cases scored
1, 2 or 3
Δ(T2 – T1) Δ(T2 – T1) Δ(T2 – T1) Δ(T2 – T1)
R7 500 115 0.00 0.00 –0.05 0.05
R6 1200 140 –0.05 0.02 –0.03 –0.08
R23 8500 300 0.02 –0.05 0.08 0.23
R10 4063 357 0.00 0.05 0.03 –0.05
R19 5000 452 –0.05 0.00 –0.15 0.28
R21 5643 475 –0.05 –0.02 0.05 0.18
R14 1800 489 0.05 0.07 0.05 –0.21
R13 1200 499 0.00 0.07 –0.21 0.00
R15 75 506 0.02 0.00 0.10 0.33
R26 – 518 –0.02 0.02 0.08 0.10
R16 1000 519 0.00 –0.04 –0.10 –0.03
R2 3000 520 –0.12 –0.10 –0.03 –0.03
R17 800 544 0.02 0.05 –0.03 –0.05
R4 1000 593 0.02 0.02 –0.03 0.07
R24 6700 616 0.02 –0.05 0.08 –0.08
R25 10,000 647 0.02 0.05 –0.08 –0.01
R22 10,000 658 0.00 0.02 0.03 0.03
R3 – 673 –0.05 –0.15 0.08 0.26
R28 6500 674 0.02 0.00 –0.03 –0.18
R27 8000 675 0.00 0.10 –0.14 –0.28
R18 8000 697 0.00 0.19 –0.21 0.23
R20 9000 714 0.00 –0.02 0.08 0.28
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TABLE 11 Change in performance between the two reads ranked according to the number of digital mammograms
read in the year prior to the first DBT read. Experience of DBT reading between the two time points is also presented
Reader
study ID
Number of
digital DBT
reads
Number of
DBT reads
between
the two
time points
Proportion of
cancer cases
recalled
Proportion of
cancer cases
scored 4 or 5
Proportion of
normal/benign
cases not
recalled
Proportion of
normal/benign
cases scored
1, 2 or 3
Δ(T2 – T1) Δ(T2 – T1) Δ(T2 – T1) Δ(T2 – T1)
R3 – 673 –0.05 –0.15 0.08 0.26
R26 – 518 –0.02 0.02 0.08 0.10
R15 75 506 0.02 0.00 0.10 0.33
R7 500 115 0.00 0.00 –0.05 0.05
R17 800 544 0.02 0.05 –0.03 –0.05
R4 1000 593 0.02 0.02 –0.03 0.07
R16 1000 519 0.00 –0.04 –0.10 –0.03
R6 1200 140 –0.05 0.02 –0.03 –0.08
R13 1200 499 0.00 0.07 –0.21 0.00
R14 1800 489 0.05 0.07 0.05 –0.21
R2 3000 520 –0.12 –0.10 –0.03 –0.03
R10 4063 357 0.00 0.05 0.03 –0.05
R19 5000 452 –0.05 0.00 –0.15 0.28
R21 5643 475 –0.05 –0.02 0.05 0.18
R28 6500 674 0.02 0.00 –0.03 –0.18
R24 6700 616 0.02 –0.05 0.08 –0.08
R18 8000 697 0.00 0.19 –0.21 0.23
R27 8000 675 0.00 0.10 –0.14 –0.28
R23 8500 300 0.02 –0.05 0.08 0.23
R20 9000 714 0.00 –0.02 0.08 0.28
R22 10,000 658 0.00 0.02 0.03 0.03
R25 10,000 647 0.02 0.05 –0.08 –0.01
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TABLE 12 Performance at the first read ranked by experience of reading FFDM in the previous 12 months
Reader
study ID
Number of
digital DBT
reads
Proportion of
cancer cases
recalled
Proportion of
cancer cases
scored 4 or 5
Proportion of
normal/benign
cases not recalled
Proportion of
normal/benign
cases scored
1, 2 or 3
R3 – 1.00 0.80 0.18 0.82
R26 – 0.98 0.88 0.15 0.62
R15 75 0.95 0.88 0.21 0.64
R7 500 0.93 0.76 0.33 0.87
R17 800 0.93 0.71 0.51 0.85
R4 1000 0.80 0.63 0.56 0.97
R16 1000 0.93 0.80 0.51 0.89
R6 1200 0.95 0.66 0.54 0.95
R13 1200 0.95 0.73 0.26 0.82
R14 1800 0.95 0.61 0.54 0.92
R2 3000 0.98 0.71 0.64 0.90
R10 4063 0.93 0.71 0.67 0.85
R19 5000 1.00 0.68 0.18 0.95
R21 5643 1.00 0.83 0.21 0.82
R28 6500 0.95 0.71 0.44 0.87
R24 6700 0.90 0.71 0.56 0.85
R18 8000 1.00 0.76 0.08 0.87
R27 8000 1.00 0.83 0.44 0.77
R23 8500 0.98 0.83 0.28 0.82
R20 9000 1.00 0.83 0.18 0.74
R22 10,000 1.00 0.85 0.18 0.74
R25 10,000 0.93 0.71 0.54 0.85
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TABLE 13 Performance at the first read ranked by years of experience reading mammograms
Reader
study ID
Years experience
reading
mammograms
Proportion of cancer cases Proportion of
normal/benign
cases not
recalled
Proportion of
normal/benign
cases scored
1, 2 or 3Recalled Scored 4 or 5
R13 25 0.95 0.73 0.26 0.82
R23 24 0.98 0.83 0.28 0.82
R25 24 0.93 0.71 0.54 0.85
R18 20 1.00 0.76 0.08 0.87
R17 18 0.93 0.71 0.51 0.85
R20 18 1.00 0.83 0.18 0.74
R2 17 0.98 0.71 0.64 0.90
R27 17 1.00 0.83 0.44 0.77
R6 15 0.95 0.66 0.54 0.95
R15 10 0.95 0.88 0.21 0.64
R19 10 1.00 0.68 0.18 0.95
R14 10 0.95 0.61 0.54 0.92
R16 7 0.93 0.80 0.51 0.89
R22 7 1.00 0.85 0.18 0.74
R28 6 0.95 0.71 0.44 0.87
R24 5 0.90 0.71 0.56 0.85
R4 4 0.80 0.63 0.56 0.97
R10 4 0.93 0.71 0.67 0.85
R21 4 1.00 0.83 0.21 0.82
R7 1.5 0.93 0.76 0.33 0.87
TABLE 14 Recall rates (suspicion score of 3 or more) by site
Site n
T1 T2 Change (T2 – T1)
Proportion
of cancer
cases
recalled
Proportion of
normal/benign
cases not
recalled
Proportion
of cancer
cases
recalled
Proportion of
normal/benign
cases not
recalled
Proportion
of cancer
cases
recalled
Proportion of
normal/benign
cases not
recalled
Aberdeen 5 0.93 0.45 0.89 0.51 –0.04 0.06
Glasgow 5 0.94 0.41 0.96 0.42 0.02 0.01
Jarvis 6 1.00 0.19 0.98 0.39 –0.01 0.20
Manchester 5 0.95 0.43 0.96 0.34 0.01 –0.09
T1, time point 1; T2, time point 2.
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TABLE 15 Cancer cases identified as suspicious or malignant (score 4 or 5) by site
Site n
T1 T2 Change (T2 – T1)
Proportion
of cancer
cases scored
4 or 5
Proportion of
normal/benign
cases scored
1, 2 or 3
Proportion
of cancer
cases scored
4 or 5
Proportion of
normal/benign
cases scored
1, 2 or 3
Proportion
of cancer
cases scored
4 or 5
Proportion of
normal/benign
cases scored
1, 2 or 3
Aberdeen 5 0.71 0.90 0.67 0.89 –0.04 –0.01
Glasgow 5 0.75 0.82 0.78 0.79 0.03 –0.04
Jarvis 6 0.80 0.82 0.82 0.80 0.02 –0.02
Manchester 5 0.77 0.79 0.79 0.77 0.02 –0.02
T1, time point 1; T2, time point 2.
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FIGURE 6 Performance at the first read ranked by number of years of experience reading mammograms.
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Discussion
As the data set was rich in difficult cases and benign abnormalities as well as cancers, it was appropriate
to look at the proportion of cancers scored 4 or 5 as well as the proportion of cancer cases recalled
(scored 3 or more). In particular, one would expect many of the non-cancer cases to be scored as 3
(probably benign), since they contained benign abnormalities.
Even though there was little change with time (Tables 8 and 9; Figures 2 and 3), there are differences
between readers, particularly when looking at cancer cases scored 4 and 5 (suspicious or malignant).
In Figure 3, it is apparent that readers choose an operating point that balances the cancer detection rate
against the proportion of normal cases scored as normal to probably benign.
Previous experience did not predict performance, in terms of either recall rates or detection of cancer.
The greatest variability between readers was seen in the proportion of normal cases not recalled.
When assessing whether or not DBT should be introduced into the screening programme, it is important
to consider extra reader time and the impact of reader fatigue. Timing reading with DBT in 2012, when
readers were relatively inexperienced, the median time for interpretation of 2D images was 17.0 seconds
with an interquartile range of 12.3–23.6 seconds, while for DBT it was 66.0 seconds, with an interquartile
range of 51.1–80.5 seconds. The difference was statistically significant (p< 0.001). Reading times were
significantly longer in FH clinics (p< 0.01). Although it took approximately four times longer to interpret
DBT than 2D images, the cases were more complex than would be expected for routine screening and had
higher mammographic density.92
There is some difference when comparing reads at time point 1 and time point 2 for one of the sites
(Jarvis). In this instance the proportion of normal/benign lesions that were not recalled increased by
20% over the course of the trial. In Manchester there was a 9% decrease in the same parameter.
The proportion of cancers identified as suspicious or malignant (4 or 5) was similar to that of cases
identified as normal/benign (1, 2 or 3) at most sites, except for Aberdeen, where the difference was 19%
at the first read and 22% at the second read.
The lack of change over time indicates that a larger set of training images is probably unnecessary,
although the intersite variations indicate that individuals operate according to local practice even under
test conditions.
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Chapter 4 Breast density assessment
Introduction
Although the risk of developing breast cancer is dependent on the cumulative impact of a wide range
of risk factors,93 increasing mammographic density has been shown to be one of the strongest
independent and modifiable predictors of breast cancer risk.4,94–100
Women with high breast density have been reported to have a four to six times increased risk of
developing breast cancer compared with those with low breast density,95,101–105 and high breast density
has also been linked to an increased risk of cancers not detected at screening,4,8,96,106,107 larger tumour
size108–110 and positive lymph nodes.109,111–113 The underlying cause of these links are thought to be
numerous, and early studies hypothesised that a significant reason for an increase in breast cancer
incidence with higher density breasts was as a result of a ‘masking bias’ that made mammographic
screening less sensitive to cancer detection.96,101 Later studies, however, have shown that there is increased
risk for at least 7–10 years following a screening examination, indicating that ‘masking bias’ is only one
of the mechanisms linking breast density to an increased cancer risk.94,101,114 In addition, the increased
radiation dose required in dense breasts and cumulative lifetime exposure from screening indicates that
there may be a less favourable benefit to harm ratio associated with screening of women with dense
breasts, particularly in younger women.93
These issues are of particular concern for the NHSBSP, as it is now extending its programme14 to include
younger, pre- or perimenopausal women, who are known to have a higher proportion of dense breast
tissue,5,115 and it is also potentially problematic for women aged 40–49 years at moderate or high risk
of developing familial breast cancer attending for annual mammography.81
It has been suggested that population mammographic screening might be more effective if screening
strategies were tailored according to mammographic breast density79 with more frequent screening or use
of magnetic resonance imaging (MRI) or adjunctive ultrasound to improve detection in women with dense
breasts.99,116–119 In this context, a campaign to include breast density in mammography reporting is currently
being debated in the USA.120 Legislation has been passed in several states mandating that breast density
be reported using the Breast Imaging Reporting and Data System (BI-RADS) scale, with women with
> 50% breast density offered supplemental screening.121
Measurement of breast density
The radiographic appearance of the breast on a mammogram reflects variations in the relative amounts
of fat, connective tissue and epithelial tissue and their different X-ray attenuation characteristics,
with breast density expressed as a percentage of the mammogram occupied by radiologically dense
fibroglandular tissue.101 Both qualitative and quantitative methods currently used to assess breast density
by mammography have limits, since they are based on the projected area rather than the volume of breast
tissue, are time-consuming, and are subject to inter- and intrareader variability.97,122 For breast density
assessment to be incorporated into a population-based screening programme such as the NHSBSP,
efficient automated methods validated against screening programme outcomes such as sensitivity,
interval cancer rates and tumour size at diagnosis are required.
Traditionally, assessment of mammographic density is performed by the radiologist evaluating the
mammogram. He/she makes a judgement on the information presented in all the mammographic views in
order to present a single score for each examination. Consistency of this measure requires an experienced
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observer to be able to correctly assess the relative proportions of glandular and fatty tissue while
accounting for variations in breast shape, radiographic texture and the presence of cancer (leading to a
localised increase in density). The radiologist is also able to take account of the variation in the radiographic
acquisition of the mammogram. These density scores can then be presented as a percentage on a
continuous scale or within discrete ranges such as the composition categories used in BI-RADS.94
Although moderate agreement has been shown between observers in assigning percentage scores of
breast density, studies suggest that training and experience are essential in ensuring that those scores are
accurate and reproducible.123,124 In addition, each manufacturer applies its own image processing, which is
often designed to minimise the effect of density in the mammogram, further increasing the difficulty of
density assessment (Dr Ralph Highnam, Matakina International Limited, 2013, personal communication).
Methods have therefore been investigated to standardise density estimates by use of automated methods.
The introduction of FFDM technologies, initially developed for digitised analogue mammograms, has
provided an opportunity to implement breast density measurement algorithms.123–126
At their simplest, these algorithms work by applying thresholds to the pixel values within the digital image
to identify the area of the image that contains the breast and then to determine the proportion of that
breast that is dense. For example, the pixel values with the highest signal can be seen to be the areas
of the image where no breast tissue has attenuated the primary X-ray beam. The areas of lowest signal,
on the other hand, represent areas where the X-rays have passed through a section of tissue that is
relatively most attenuating.127
Later developments have led to software that estimates the volume of dense fibroglandular tissue rather
than just the area projected onto the mammogram. By using the image pixel data in combination with
information about its acquisition found the DICOM data file, sophisticated algorithms are able to provide
measurements of the relevant tissue volumes. For example, data regarding the breast thickness and the
X-ray exposure’s tube potential, current, time, target and filter – in combination with knowledge of the
radiation attenuation properties of different tissues – can enable a derivation of the breast composition
represented by each pixel.97,128 Improvements in the measurement are then made through advances in this
derivation, for example providing better calibration of the image data and breast thickness estimation.129
Two software tools were used in this study. Hologic’s Quantra has been validated and found to have good
agreement with measurements of breast density from MRI data and reader assessments.121,128 Matakina’s
Volpara™ software has similarly found to be in good agreement with MRI and observer measurements of
breast density.121,130
The aim of this substudy within the trial was to evaluate and utilise two of the commercially available software
packages for the measurement of volumetric breast density and compare these with observer-based scores
of area density. This data would then be correlated with the results of the retrospective reading study
designed to determine if the addition of DBT improved the detection of cancers in women at higher risk of
developing breast cancer due to increased breast density. A secondary aim of this study was to assess whether
or not there is a relationship between breast density and breast cancer incidence.
Materials and methods
In the prospective data collection phase of the trial, readers were asked to assess breast density on a
10-cm VAS.129 The markings on this scale were then converted into a score ranging from 0 to 100%.
The two software packages used to assess the volumetric density of each mammogram were Quantra and
Volpara. Each program’s output consisted of a number of results, including values for the absolute volume
of fibroglandular tissue and overall breast volume as well as the volumetric breast density on a per image
basis. Scores from each image of a full examination were then combined to derive a score for each case.
BREAST DENSITY ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
Each software vendor provides an ability to combine these automatically. However, we chose to adapt
the underlying logic provided by the Quantra system (Dr Ashwini Kshirsagar, Hologic Inc., 2013, personal
communication) to minimise the effect of lesion presence on the result. Their generally applied logic takes
the maximum total breast and fibroglandular tissue volumes calculated from the CC and MLO images.
The values for left and right breasts are then added and the overall density determined. We believe this
to be in line with the behaviour of observers and with findings from prevalence studies that risk may
be associated with the density derived on the contralateral mammogram in the absence of prior imaging.101
In order to obtain the overall score for each examination, the absolute values of total breast volume
and fibroglandular tissue for each of the four views (left and right, CC and MLO) were examined.
For cases where no cancer was assessed as being present, the largest results for each breast (from either
the CC or the MLO view) were determined and the average volumes of the two breasts were calculated.
For cases where cancer was confirmed, results were used from the contralateral breast. If no contralateral
data were available, results from the affected breast were used. Volumetric density was calculated from
the ratio of the fibroglandular tissue volume to the overall breast volume. The same logic was applied to
the scores given by the Quantra system for area breast density, which should nominally be comparable
with the observer scores.
With these density scores the aim of this study was to compare the observer’s score with the automated
techniques (Quantra and Volpara), to establish any age-related correlation with density and to establish
if cancer incidence is associated with breast density. Pathology reports were used to confirm cancer cases.
Results
A total of 8867 women’s standard 2D mammograms acquired for the trial were available for analysis. The
software was unable to produce scores for every image analysed. Reasons for algorithm failure were varied
but included magnification views where there was no background detected; cases in which information
given in the DICOM image header was inconsistent with that normally expected in mammography, for
example non-female gender selection; and invalid filter types or improbable thicknesses (e.g. 0 cm
or > 30 cm).
The summary results for the study cohort are shown in Table 16. In total, 8391 cases were given an overall
density score by the observers on the VAS, 8512 cases were calculated from scores from Quantra analysis
of 33,966 images and 8532 cases were calculated from scores from Volpara analysis of 34,755 images.
TABLE 16 Summary results for the total cohort of cases. Unless indicated, numbers are median
(minimum–maximum) values
Measurements Observers Quantra Volpara
Cases (n) 8391 8512 8532
Breast volume (cm3) – 953.5 (73.0–4986.5) 921.4 (33.4–5009.3)
Fibroglandular tissue volume (cm3) – 93.0 (4.0–1024.0) 71.6 (6.8–628.5)
Area breast density (%) 36.8 (0.0–100.0) 14.8 (0.0–76.5) –
Volumetric breast density (%) – 9.5 (1.4–56.2) 7.7 (2.5–54.2)
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Total breast volume
Figures 9 and 10 illustrate the distribution and comparison of total breast volume as measured by the
Quantra and Volpara software throughout the study population. The two systems show a very good linear
correlation with a coefficient of determination of 0.95. The mean difference between the values calculated
for each case is 5.04% (± 0.32%, two standard errors), suggesting good agreement between the
two systems.
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FIGURE 9 Histograms showing the distribution of breast volume across the study population as measured by
(a) Quantra and (b) Volpara.
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FIGURE 10 Scatterplot comparing Quantra and Volpara scores for total breast volume.
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Fibroglandular tissue volume
Figures 11 and 12 show the results for the fibroglandular tissue volume within the breast. The coefficient
of determination for a linear correlation is 0.74 and the mean difference between the values calculated for
each case is 21.19% (± 0.72%), with Quantra giving the larger of the two values. Our understanding is
that this is because of differences in the way that each system handles the density associated with the skin
within the assessment of fibroglandular volume. The differences between the two systems appear to get
larger as the amount of fibroglandular tissue increases. This is particularly noticeable above 400 cm3.
In addition, the range of results for fibroglandular volume is greater for the Quantra system, with most
values lying between 0 and 400 cm3 as opposed to Volpara’s results lying between 0 and 300 cm3.
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FIGURE 11 Histograms showing the distribution of fibroglandular tissue volume across the study population
as measured by (a) Quantra and (b) Volpara. The x-axes of each graph are designed to match for clarity but seven
cases in the Quantra data set had volumes greater than 800 cm3.
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Volumetric breast density
Figures 13 and 14 show the results for the volumetric breast density. The coefficient of determination
for a linear correlation is 0.65 and the mean difference between the values calculated for each case
is 16.32% (± 0.69%).
Figures 15 and 16 show the results for breast density estimated from the projected mammogram, the
area-based breast density scored by the observers, and the Quantra software. The Volpara software did
not give an area-based density result. There is poor correlation between the two measurements, with a
coefficient of determination for a linear correlation of 0.31.
Figure 17 compares the area-based breast density scored by the observers, and the volumetric density
measurement from each program. The coefficient of determination for an exponential correlation is 0.33
and 0.38 for the Quantra and Volpara systems, respectively. The large values given at each 5% mark on
the observers’ histograms in Figures 14 and 16 are a consequence of the way that the VAS scale was
processed in two centres, with one rounding results to within the nearest 5% and the other the
nearest 10%.
For FH cases, density was assessed by two observers from the same centre, giving us 638 cases with
two scores for comparison. In 70% of these cases the score agreed to within 10%; however, 8% of
cases disagreed by more than 20%.
Figure 18 shows the variation with decade of age in the four breast densities measures examined
in this work.
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FIGURE 12 Scatterplot comparing Quantra and Volpara scores for fibroglandular tissue volume.
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FIGURE 13 Histograms showing the distribution of volumetric breast density across the study population as
measured by (a) Quantra and (b) Volpara.
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FIGURE 14 Scatterplot comparing Quantra and Volpara scores for volumetric breast density.
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FIGURE 15 Histograms showing the distribution of area-based breast density across the study population from
(a) the observers and (b) the Quantra software.
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FIGURE 16 Scatterplot comparing the observer and Quantra scores for the area-based breast density.
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FIGURE 17 Scatterplots comparing the observer area-based breast density scores with the volumetric
measurements from (a) Quantra and (b) Volpara.
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FIGURE 18 Graphs showing the decrease in breast density with age for the study group for the four available
density measures. Error bars are two standard errors of the mean. (a) Area-based density in the observers;
(b) area-based density in the Quantra; (c) volume-based density in Quantra; and (d) volume-based density
in Volpara. (continued )
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FIGURE 18 Graphs showing the decrease in breast density with age for the study group for the four available
density measures. Error bars are two standard errors of the mean. (a) Area-based density in the observers;
(b) area-based density in the Quantra; (c) volume-based density in Quantra; and (d) volume-based density
in Volpara.
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Breast density and cancer risk
Volpara breast composition data were available for 7019 of the 7060 cases (1157 of the 1160 cancers and
5862 of the 5900 non-cancers). Table 17 shows mean and standard deviation of breast composition
measures using Volpara, by age, cancer status and cohort (assessment or FH screened). The absolute dense
volume was generally higher in cancers than in non-cancers and declined with age in all groups. The
percentage density showed the same tendencies, although less markedly. Adjusting for age, there was a
significant effect of Volpara absolute dense volume on risk of cancer, with a 3% increase in odds of cancer
per additional 10 cm3 of dense tissue [odds ratio (OR)= 1.03, 95% CI 1.01 to 1.05, p< 0.001]. The effect of
dense volume on risk did not vary significantly by age (p= 0.2). Figure 19 shows the ORs and 95% CIs by
quartile of absolute dense volume. There was no significant effect of percentage density on risk (p= 0.7).
Corresponding information for Quantra breast composition data was available for 7005 cases
(1156 cancers and 5849 non-cancers). Table 18 shows the means and standard deviations of the Quantra
measurements by age, cancer status and cohort. Again, dense volume was generally higher in cancers
and declined with age. Adjusting for age, there was a significant effect of Quantra absolute dense volume
on cancer risk, with a 2% increase in risk per additional 10 cm3 of dense tissue (OR= 1.02, 95% CI 1.01 to
1.03, p< 0.001). The effect did not vary significantly by age (p= 0.1). Figure 20 shows the ORs by quartile
of Quantra density. There was also a significant effect of Quantra percentage density on risk, although
this was less significant than that of absolute dense volume, with a 9% increase in risk per 5% increase
in per cent density (OR= 1.09, 95% CI 1.02 to 1.16, p= 0.01). Table 19 shows the ORs by quartile of
Quantra percentage density.
Of the three measures which were significantly associated with breast cancer risk, the highest standardised
OR (OR per standard deviation of the measure) was observed for Volpara absolute density, 1.1718, with
Quantra absolute density being very close to this, 1.1661. Quantra per cent density had a considerably
lower standardised OR, 1.1076.
TABLE 17 Breast composition measures using Volpara
Age (years)
Breast composition
measure
Mean (SD) for population
Cancers
Assessment
non-cancers FH non-cancers All non-cancers
< 50 Breast volume (cm3) 1063 (663) 1027 (673) 1041 (668) 1037 (669)
Dense volume (cm3) 111 (53) 101 (67) 101 (61) 101 (63)
% density 13 (7) 12 (6) 12 (7) 12 (7)
No. of subjects 29 313 942 1255
50–59 Breast volume (cm3) 1153 (670) 1034 (614) 983 (597) 1033 (613)
Dense volume (cm3) 94 (54) 84 (50) 84 (51) 84 (50)
% density 10 (6) 9 (5) 10 (5) 10 (5)
No. of subjects 460 3092 43 3135
≥ 60 Breast volume (cm3) 1092 (562) 1010 (557) 582 (75) 1009 (556)
Dense volume (cm3) 77 (44) 73 (43) 53 (20) 73 (43)
% density 8 (4) 8 (4) 9 (2) 8 (4)
No. of subjects 660 1402 3 1405
All ages
(including
age missing)
Breast volume (cm3) 1116 (613) 1028 (601) 1040 (662) 1030 (613)
Dense volume (cm3) 85 (49) 82 (49) 100 (61) 85 (52)
% density 9 (5) 9 (5) 12 (7) 10 (6)
No. of subjects 1157 4830 1032 5862
SD, standard deviation.
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FIGURE 19 Odds ratios by quartile of Volpara absolute dense volume. Quartile 1, < 51 cm3; quartile 2, 51–71.99 cm3;
quartile 3, 72–102.99 cm3; and quartile 4, > 103 cm3. Vertical lines indicate 95% CIs.
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FIGURE 20 Odds ratios by quartile of Quantra absolute dense volume. Quartile 1, < 59 cm3; quartile 2, 59–92.99 cm3;
quartile 3, 93–142.99 cm3; and quartile 4, > 143 cm3. Vertical lines indicate 95% CIs.
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Discussion
The striking result from this analysis is the lack of correlation between observer scores of breast density
and an automated analysis. Observer measurement of breast density has been shown in other studies
to suffer from interobserver variability123,124,131,132 and a recent paper has attempted to provide a correction
for differences between observers.133
From our results it is clear that observers are able to discriminate different densities in subjects
with low automated breast densities. However, when examining the histograms, shown in Figure 14,
of the area-based measurements from both human observers and software analysis, there is clearly
a difference in the distribution of scores. This may in part be a result of the observers applying a
semi-volumetric approach to the assessment rather than a purely area-based one (Dr Ralph Highnam,
Matakina International Limited, 2013, personal communication); however, when we compare
the distribution with those found in the literature for visual and threshold methods,131,134 it is the software
TABLE 19 Odds ratios by quartile of Quantra percentage density
% density OR 95% CI
< 7 1.00 –
7–9.99 1.20 1.00 to 1.43
10–13.99 1.08 0.88 to 1.33
≥ 14 1.40 1.14 to 1.72
TABLE 18 Breast composition measures using Quantra
Age (years)
Breast composition
measure
Mean (SD) for population
Cancers
Assessment
non-cancers FH non-cancers All non-cancers
< 50 Breast volume (cm3) 1118 (723) 1075 (696) 1088 (681) 1085 (685)
Dense volume (cm3) 143 (99) 142 (128) 137 (99) 138 (107)
% density 14 (7) 14 (7) 14 (7) 14 (7)
No. of subjects 29 313 938 1251
50–59 Breast volume (cm3) 1195 (670) 1079 (636) 1044 (602) 1078 (636)
Dense volume (cm3) 131 (93) 114 (99) 111 (82) 114 (88)
% density 12 (6) 11 (6) 13 (9) 11 (6)
No. of subjects 459 3088 43 3131
≥ 60 Breast volume (cm3) 1126 (582) 1054 (570) 612 (121) 1052 (570)
Dense volume (cm3) 104 (71) 97 (76) 57 (41) 97 (76)
% density 9 (5) 9 (5) 9 (5) 9 (5)
No. of subjects 660 1402 3 1400
All ages
(including
age missing)
Breast volume (cm3) 1156 (642) 1073 (622) 1088 (678) 1075 (632)
Dense volume (cm3) 116 (83) 111 (88) 135 (97) 115 (90)
% density 11 (5) 11 (6) 14 (7) 11 (6)
No. of subjects 1156 4821 1028 5849
SD, standard deviation.
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that produces the more comparable distribution. Results for the FH cases where two observers have scored
the same images show that in 70% of cases there was good agreement. In 8% of cases there was,
however, a disagreement of more than 20%, which is a result that has been noted elsewhere.132,135
It should be noted that, although the observers were experienced at reading mammograms, they do not
routinely estimate breast density in the NHSBSP. However, in the UK in symptomatic practice, diagnostic
mammograms are categorised to a three-point scale (fatty, mixed and dense).
One possible technical reason for the difference in observer-based density scores and automated scores
could be the processing of the displayed image. The software analyses the raw digital data. The observers
make their estimation of density on processed images optimised for display on the workstation and have
the ability to alter the window width and level of the greyscale applied to the image’s pixels. This
adjustment can significantly alter the image presentation and, therefore, potentially affect the density
estimate. In this study, readers were advised not to alter the window levels. Comparing the two
automated techniques, it can be seen that there is very good agreement when evaluating the overall
breast volume. This is presumably a result of the relative ease with which each algorithm identifies
the breast against the background, while each applies its own proprietary corrections to account
for compression paddle height and tilt.121,128,130
There was a less agreement in the assessment of the fibroglandular volumes. There was relatively good
agreement at lower volumes; however, it became poorer as those volumes increased, particularly above
400 cm3. This then led to differences in the resulting volumetric density measurements. The reasons for this
discrepancy are unclear but are most likely a result of the different methods used by each software tool.
Each algorithm allocates differing ratios of fibroglandular, adipose and skin tissues to each pixel based
on their relative X-ray attenuation with reference to pixels in the image defined at pure adipose or fatty
tissue.121 As density increases, it becomes harder to identify these reference areas and each manufacturer’s
solution to this problem is likely to result in differences in the final volumetric density results.121,128
Some images produced quite different results as indicated by the outliers present in the fibroglandular
volume and volumetric density scores shown in Figures 11 and 13. Further review of the images
contributing to these outliers suggest that, on rare occasions, ‘non-standard’ image presentation can
result in an incorrect estimation of the relevant tissue volumes while not triggering an error message
in the results.
For example, in one left MLO view, the presence of a pacemaker resulted in significantly different results
for fibroglandular tissue volume, with Volpara software scoring 425 cm3 and Quantra software scoring
303 cm3, leading to volumetric densities of 19.4% and 13%, respectively, for that image. A mammogram
of a visibly extremely dense breast with unusual texture resulted in each system producing very different
scores for all of the volume measures, including overall breast volume. The cause of this is unknown but
again may be a result of the software requiring a particular reference point where the tissue composition
is assumed, for example pixels that are entirely composed of fat. Such reference points may have been
difficult to locate in such a dense image. Finally, significant differences in scores were found in an image
where tissue was missing from the edge of the mammogram.
Analysis of the relationship between cancer incidence and volumetric density has shown that there
is a significant association of increased risk with density. This relationship was seen to be stronger
with absolute measurements of the fibroglandular tissue volume than the percentage volume from both
the Quantra and Volpara software. The ORs calculated here are lower than those found in the literature;136
however, this population may be biased and not reflective of the general screening population. In addition,
only screen-detected cancers were included here. Interval cancers collected in the future may show this
study to have underestimated the risk.
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If volumetric density is to be used to estimate breast cancer risk, it is important that the measurements
be reliable. It is also important to understand that there are technical differences in the way in which each
software package determines the fibroglandular tissue volume, and therefore the density. In addition,
any long-term monitoring of breast density may require careful consideration if switching measurement
methodology. The effect of the individual machine acquisition parameters and image processing together
with the use of different software algorithms is worthy of further investigation to determine the overall
effect on density scores in order that longitudinal studies can be undertaken.
The literature indicates that breast density may be an independent risk factor for breast cancer but
is also correlated with age and body mass index and may be modified by hormone replacement therapy,
FH and ethnicity.93,101 Figure 17 illustrates the variation with age, and any attempt to use density to assess
risk must take such confounding factors into consideration.
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Chapter 5 Results
Recruitment
A total of 8869 participants were recruited from the six participating centres over a 21-month period
(Tables 20 and 21 and Figure 21). This data set comprised 7684 assessment cases and 1185 cases
from women aged 40–49 years at moderate or high risk of developing breast cancer owing to their FH
(subsequently referred to as FH cases). The latter group was included to provide a group of cases with
higher breast density for subanalysis of the impact of breast density on the diagnostic accuracy of DBT.
At the start of recruitment, some centres were still in the process of setting up annual screening
(National Institute for Health and Care Excellence Familial Breast Cancer Guidelines) for FH women;81
therefore, recruitment in this subgroup was at a slower rate initially. However, an interim analysis of data
indicated that the trial was approaching its proposed recruitment target of 7000 cases, but with only 12%
cancer cases, as opposed to the 18% predicted. The trial management group decided in September 2012
to cease recruitment of FH cases and continue with recruitment of a further 2000 assessment cases to
provide sufficient cancer cases to give 90% power.
Data sets
After exclusions had been applied (n= 207), we were left with a prospective data set of 8662 cases
(Figure 22). Not all of these could be included in the retrospective reading study, since we were restricted
to reading only around 7000 owing to budget and time constraints. In total, 1412 cases were not
allocated to the reading study. These included those cases with which there were problems in image
transmission resulting in an incomplete set of images. Issues around transmission of images are described
in Appendix 1. These appear to have been random and not attributable to any particular type, for example
those with larger files. Problems were more likely to be a result of timing of image transfer, speed of
connection and various system firewalls. This resulted in a reading study data set of 7250 cases (Figure 22).
There were a few cases (n= 190) for which we collected data for only one arm of the study. This was
either because the case was not allocated to be read in any other arm (e.g. logistics, not being converted
to 2D synthetic, image management issues) or because the data were not received back from sites
(lost in transit, logistics). Discounting these resulted in a final data set for analysis of 7060 cases
(assessment cases: n= 6020, FH cases: n= 1040; Figure 22).
TABLE 20 Recruitment by centre
Centre Assessment FH All
Aberdeen 641 318 959
Glasgow 2097 0 2097
Manchester 1593 486 2079
King’s College 942 115 1057
Barts 1004 18 1022
Guildford 1407 248 1655
Total 7684 1185 8869
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TABLE 21 Recruitment summary
Month Assessment FH All Cumulative
July 2011 77 0 77 77
August 2011 252 17 269 346
September 2011 374 18 392 738
October 2011 339 23 362 1100
November 2011 369 76 445 1545
December 2011 309 75 384 1929
January 2012 521 81 602 2531
February 2012 618 141 759 3290
March 2012 455 96 551 3841
April 2012 409 86 495 4336
May 2012 466 136 602 4938
June 2012 283 83 366 5304
July 2012 375 89 464 5768
August 2012 468 134 602 6370
September 2012 419 113 532 6902
October 2012 422 17 439 7341
November 2012 454 0 454 7795
December 2012 277 0 277 8072
January 2013 413 0 413 8485
February 2013 309 0 309 8794
March 2013 75 0 75 8869
Total 7684 1185 8869
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Analysis
After exclusions, there were a total of 7060 subjects for analysis. The data set comprised 6020
(1158 cancers) assessment cases and 1040 (two cancers) FH surveillance cases. Reading data were available
for 6927 (98%) cases by 2D only, 6959 (99%) by 2D+DBT and 6653 (94%) by 2D synthetic+DBT.
Table 22 shows the characteristics of the study population.
The analysis included cases which were read in only two arms of the study to avoid introducing bias.
It was run again using only cases which were read in all three arms and produced identical results.
Exclusions
(n = 207; 21)
Incomplete images received,
Duplicate R2ID/R2NUM allocated,
Withdrawn,
Data issues at recruitment site,    
n = 26
n = 138
n = 3
n = 40
Number of women recruited
(n = 8869; 1311)
Assessment, n = 7684 (1308)
FH, n = 1185 (3) 
Assessment, n = 7477 (1287)
FH, n = 1185 (3) 
Assessment, n = 1281 (115)
FH, n = 131 (0) 
Assessment, n = 6196 (1172)
FH, n = 1054 (3) 
Assessment, n = 176 (14)
FH, n = 14 (1) 
Prospective data set
(n = 8662; 1290)
Not allocated to reading study
(n = 1412; 115) 
Reading study data set
(n = 7250; 1175)
Analysis data set
(n = 7060; 1160)
Cases with data for one reading arm only
(n = 190; 15)
FH cases for analysis
(n = 1040; 2)
Assessment cases for analysis
(n = 6020; 1158)
FIGURE 22 Study flow chart. Green text represents the total number of women; blue text presents the number
of women with cancer.
DOI: 10.3310/hta19040 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 4
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
TABLE 22 Participant characteristics
Characteristics
Assessment cases FH cases
Number randomised
(%)a
Number of cancers
(%)a
Number randomised
(%)a
Number of cancers
(%)a
Age range (years)
< 40 3 (< 1) 1 (< 1) 11 (1) 0
40–49 340 (6) 27 (2) 938 (94) 1 (50)
50–59 3568 (59) 462 (40) 44 (4) 1 (50)
60–69 1714 (29) 519 (45) 3 (< 1) 0
≥ 70 364 (6) 141 (12) 0 0
Unknown 31 9 44 0
Breast density (%)
0–24 1636 (27) 378 (33) 233 (23) 0
25–49 2556 (43) 439 (38) 418 (42) 1 (50)
50–74 1376 (23) 271 (24) 271 (27) 1 (50)
75–100 396 (7) 63 (5) 83 (8) 0
Unknown 56 8 35 0
Cancer type
Invasive ductal
(±DCIS)
– 788 (68) – 1 (50)
Invasive lobular
(±DCIS)
– 109 (9) – –
Invasive other
(±DCIS)
– 59 (5) – –
DCIS – 203 (18) – 1 (50)
Cancer size (mm)
Invasive cancers
1–5 – 73 (8) – 0
6–10 – 243 (26) – 0
11–20 – 434 (46) – 1 (100)
21–50 – 183 (19) – 0
> 50 – 10 (1) – 0
Unknown – 13 – 0
DCIS
1–5 – 30 (15) – 0
6–10 – 30 (15) – 0
11–20 – 47 (24) – 0
21–50 – 78 (39) – 1 (100)
> 50 – 15 (7) – 0
Unknown – 3 – 0
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TABLE 22 Participant characteristics (continued )
Characteristics
Assessment cases FH cases
Number randomised
(%)a
Number of cancers
(%)a
Number randomised
(%)a
Number of cancers
(%)a
Cancer grade
Invasive cancers
1 – 242 (26) – 0
2 – 504 (54) – 2 (100)
3 – 180 (20) – 0
Unknown – 30 – 0
DCIS
Low – 10 (8) – 0
Intermediate – 31 (22) – 1 (100)
High – 97 (70) – 0
Unknown – 65 – 0
Lymph node status (invasive cancers only)
Normal – 514 (58) – 0
< 4 nodes positive – 292 (33) – 1 (100)
4 or more
nodes positive
– 77 (9) – 0
Unknown – 73 – 0
Dominant radiological feature
Circumscribed mass 1814 (30) 145 (13) 84 (8) 0
Spiculated mass 712 (12) 508 (44) 3 (< 1) 0
Microcalcification 1006 (17) 282 (24) 40 (4) 1 (50)
Distortion 514 (8) 109 (9) 10 (1) 1 (50)
ASD 1837 (31) 107 (9) 26 (3) 0
None 137 (2) 7 (1) 877 (84) 0
Recruitment site
Aberdeen 602 (10) 83 (7) 288 (28) 0
Glasgow 1362 (23) 259 (23) 0 0
Manchester 1280 (21) 237 (20) 386 (37) 1 (50)
Guildford 1183(20) 249 (22) 239 (23) 1 (50)
King’s College 760 (12) 165 (14) 116 (11) 0
Barts 833 (14) 165 (14) 11 (1) 0
a Percentages have been reported for known data.
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In addition to the matched data available for 1137 cancer cases which had both 2D and 2D+DBT
imaging, unmatched data were available for 18 cases for 2D imaging only and for another five cases for
2D+DBT imaging only. Pooling the matched and the unmatched data and analysing with a modification
of the Mantel–Haenszel method137 resulted in an OR for cancer detection (2D+DBT vs. 2D alone) of 1.363
(95% CI 1.002 to 1.852, p= 0.048), indicating significantly better sensitivity for 2D+DBT than 2D alone.
Table 23 shows sensitivity and specificity for specific subgroups and for all subjects combined. For all
subjects combined, sensitivity was 87% (95% CI 85% to 89%) for 2D only, 89% (95% CI 87% to 91%)
for 2D+DBT and 88% (95% CI 86% to 90%) for synthetic 2D+DBT. The difference in sensitivity
between 2D and 2D+DBT was of borderline significance (p= 0.07). There was no significant difference
in sensitivity between 2D and synthetic 2D+DBT (p= 0.6). Specificity was 58% (95% CI 56% to 60%)
for 2D, 69% (95% CI 67% to 71%) for 2D+DBT and 71% (95% CI 69% to 73%) for synthetic 2D+DBT.
Specificity was significantly higher for 2D+DBT and for synthetic 2D+DBT than for 2D
(p< 0.001 in both cases).
The increased specificity with 2D+DBT and synthetic 2D+DBT was observed in all subgroups of density
and dominant radiological feature and across all age groups (p< 0.001 in all cases). Specificity tended
to be lower by all three modalities for microcalcifications and higher by all three modalities for distortion/
ASD density, but the significant improvement in specificity for both 3D modalities was consistently
observed in these categories.
Sensitivity was significantly higher (p= 0.01) for 2D+DBT than 2D alone for age range 50–59 years. Sensitivity
was significantly higher (p< 0.001) for 2D+DBT than for 2D alone for invasive tumours of size 11–20mm,
with a sensitivity of 86% (95% CI 82% to 90%) for 2D and 93% (95% CI 90% to 96%) for 2D+DBT.
For the purposes of analysis stratified by density, we classified density as below 50% or 50% and above.
We had planned to use 70% density as the cut-off, but there were only 105 cancer cases with density
of 70% or more.
Significantly higher sensitivity (p= 0.03) was also observed for 2D+DBT for those with density 50%
or more, with a sensitivity of 86% (95% CI 82% to 90%) for 2D compared with 93% (95% CI 90%
to 96%) for 2D+DBT. A similarly increased sensitivity (p= 0.01) was seen for 2D+DBT in grade 2 invasive
tumours (but not grade 1 or grade 3), with sensitivity of 87% (95% CI 84% to 90%) for 2D and 91%
(95% CI 88% to 94%) for 2D+DBT. A significant increase in sensitivity was observed for 2D+DBT
(p= 0.04) where the dominant radiological feature was a mass, with 89% (95% CI 86% to 92%)
sensitivity for 2D and 92% (95% CI 89% to 95%) for 2D+DBT.
For synthetic 2D+DBT, there was significantly (p= 0.006) higher sensitivity than for 2D alone in invasive
cancers of size 11–20mm, with a sensitivity of 92% (95% CI 89% to 95%). No other significant
differences in sensitivity were noted.
Table 24 shows the distribution of detection of cancers for all combinations of modalities in those 1112
cancers for which we have reading data for all three reading arms. In total, 1079 (97%) cancers were
detected by at least one reading arm; 840 (75%) cancers were detected by all three reading arms. A total
of 142 (13%) cancers were missed by 2D, 118 (11%) by 2D+DBT and 136 (12%) by synthetic 2D+DBT.
Of these, 33 (3%) cancers were missed in all three reading arms. DCIS cases showed similar distribution
to all cancers combined.
Table 25 shows characteristics of these missed cancers for each imaging modality, plus those found
by all three modalities. Two major differences among the modalities were that cancers missed by 2D alone
tended to be of size 11–20mm or to have a mass as the major radiological sign, compared with the other
two modalities; and cancers missed by 2D+DBT were less likely to be of grade 2 or to have density less
than 50% than the other two modalities.
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TABLE 24 Detection status of cancers all three imaging modalities
Detected by
Number of cancers (%) Number of DCIS cases (%)2D 2D+DBT Synthetic 2D + DBT
No No No 33 (3) 6 (3)
No No Yes 16 (1) 4 (2)
No Yes No 18 (2) 2 (1)
No Yes Yes 75 (7) 14 (7)
Yes No No 24 (2) 8 (4)
Yes No Yes 45 (4) 8 (4)
Yes Yes No 61 (6) 15 (8)
Yes Yes Yes 840 (75) 143 (71)
Total 1112 200
TABLE 25 Characteristics of invasive cancers missed by each imaging modality and of those found by all three
Factor Category
Number of
cancers missed
by 2D only (%)
Number of
cancers missed
by 2D+DBT (%)
Number of
cancers missed
by synthetic
2D+DBT (%)
Number of
cancers found
by all three
modalities (%)
Size (mm) 1–10 47 (39) 47 (50) 48 (47) 207 (30)
11–20 60 (50) 30 (32) 34 (34) 326 (47)
> 20 14 (11) 17 (18) 19 (19) 155 (23)
Node status Negative 62 (54) 51 (56) 55 (56) 388 (60)
1–3 positive 41 (36) 35 (38) 35 (35) 201 (31)
> 3 positive 11 (10) 5 (6) 9 (9) 55 (9)
Grade 1 34 (29) 26 (29) 27 (27) 164 (24)
2 67 (56) 43 (48) 57 (56) 373 (55)
3 18 (15) 21 (23) 17 (17) 140 (21)
Breast density < 50% 80 (66) 69 (73) 70 (66) 488 (70)
≥ 50% 42 (34) 26 (27) 36 (34) 195 (30)
Dominant
radiological feature
Mass 68 (55) 45 (47) 52 (49) 479 (69)
Microcalcification 12 (10) 12 (13) 16 (15) 88 (12)
Distortion/ASD 42 (34) 37 (39) 37 (35) 126 (18)
None 1 (1) 1 (1) 1 (1) 4 (1)
DOI: 10.3310/hta19040 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 4
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53
Receiver operating characteristic analysis
Receiver operating characteristic analysis was performed to compare the diagnostic accuracy
of the three reading arms (2D alone vs. 2D+DBT vs. synthetic 2D+DBT) by calculating the AUC and
p-value. Areas under the curve were compared using the method of DeLong et al.91
Figure 23 shows the ROC curve for each reading arm on the same graph.
For 2D alone, the AUC was 0.84 (95% CI 0.83 to 0.86), for 2D+DBT the AUC was 0.89 (95% CI 0.87
to 0.90) and for synthetic 2D+DBT the AUC was 0.87 (95% CI 0.86 to 0.89). Both 2D+DBT and
synthetic 2D+DBT had significantly greater AUCs than 2D alone (p< 0.001 in both cases).
Although, in general, specificity was considerably higher for the two DBT arms at very low levels
of sensitivity, 2D alone would have a slightly higher specificity than 2D+DBT or synthetic 2D+DBT.
However, thereafter, the ROC curves for the two DBT arms would always be higher than for 2D alone.
ROC analysis was also carried out on specific subgroups:
i. cases with visually assessed density of less than 50%
ii. cases with visually assessed density of 50% or more
iii. cases where the dominant radiological sign was a soft-tissue mass
iv. cases where the dominant radiological feature was microcalcification
v. cases where the dominant radiological feature was asymmetry or distortion.
Figure 24 shows the ROC curves for the three reading arms in those cases with visually assessed breast
density of less than 50%. The AUCs were 0.85 (95% CI 0.83 to 0.87) for 2D alone, 0.89 (95% CI 0.87
to 0.90) for 2D+DBT and 0.88 (95% CI 0.86 to 0.90) for synthetic 2D+DBT. The AUCs for 2D+DBT
and synthetic 2D+DBT were significantly greater than that for 2D alone (p< 0.001 in both cases).
Figure 25 shows the corresponding curves in those with visually assessed density of 50% or more. The AUCs
were 0.83 (95% CI 0.80 to 0.86) for 2D alone, 0.89 (95% CI 0.87 to 0.92) for 2D+DBT and 0.87
(95% CI 0.84 to 0.89) for synthetic 2D + DBT. Both 2D+DBT (p< 0.001) and synthetic 2D+DBT (p= 0.005)
had significantly greater AUCs than 2D alone.
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FIGURE 23 Receiver operating characteristic curves for the three reading arms.
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Figure 26 shows the ROC curves in those subjects in whom the dominant radiological feature was a mass.
The AUCs were 0.86 (95% CI 0.84 to 0.88) for 2D alone, 0.92 (95% CI 0.90 to 0.94) for 2D+DBT
and 0.91 (95% CI 0.89 to 0.93) for synthetic 2D+DBT. The AUCs for 2D+DBT and for synthetic
2D+DBT were significantly greater than for 2D alone (p< 0.001 in both cases).
The corresponding curves for those with microcalcifications as the dominant sign are shown in
Figure 27. The AUCs were 0.73 (95% CI 0.69 to 0.77) for 2D alone, 0.73 (95% CI 0.69 to 0.77) for
2D+DBT and 0.72 (95% CI 0.68 to 0.76) for synthetic 2D+DBT. The AUCs did not differ significantly
from 2D alone for either 2D+DBT (p= 0.9) or synthetic 2D+DBT (p= 0.8).
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FIGURE 24 Receiver operating characteristic curves for the three reading arms in those cases with visually assessed
density less than 50%.
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FIGURE 25 Receiver operating characteristic curves for all three reading arms in those with visually assessed density
of 50% or more.
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Figure 28 shows the ROC curves for those with distortion or asymmetry as the dominant radiological
feature. The AUCs were 0.82 (95% CI 0.78 to 0.86) for 2D alone, 0.86 (95% CI 0.82 to 0.89)
for 2D+DBT and 0.87 (95% CI 0.83 to 0.90) for synthetic 2D+DBT. Significantly greater AUCs than
for 2D alone were noted for both 2D+DBT (p= 0.03) and 2D synthetic+DBT (p= 0.002).
These differences in AUC are mostly driven by differences in specificity, including the low AUCs for
all three reading arms in those with calcifications as the dominant radiological feature. However, there
is clearly a shift to greater confidence in malignancy among cancers with the addition of DBT. With 2D
alone, 39% of cancers were scored as 5 (malignant), whereas in both 2D+DBT and synthetic 2D+DBT
53% of cancers were scored as 5.
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FIGURE 26 Receiver operating characteristic curves for the three reading arms in those cases where the dominant
radiological sign was a mass.
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FIGURE 27 Receiver operating characteristic curves for the three reading arms in those cases with
microcalcifications as the dominant radiological feature.
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FIGURE 28 Receiver operating characteristic curves for all three reading arms in those with distortion or ASD as the
dominant radiological feature.
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Chapter 6 Discussion
In this retrospective reading study, our primary paired data analysis demonstrated only a modestimprovement in cancer detection rate but a clear improvement in specificity when DBT is used
in conjunction with 2D images or synthetic images compared with 2D alone. However, evidence
of a significant increase in sensitivity for 2D+DBT compared with 2D alone was noted in a secondary
analysis that pooled together the matched and unmatched data for cases where there were incomplete
data for one of the reading arms of the study.
Non-significant increases in cancer detection ranging from 4.3% to 49.0% have been reported in several
screening studies after the addition of DBT;59,60,138,139 in these cases lack of statistical significance was
largely attributable to sample size limitations. Our results differ from data from two prospective screening
trials comparing 2D+DBT and 2D alone. Significant increases in cancer detection rate, of 27% and 34%,
were reported in the Oslo19 and STORM66 trials, respectively. In addition, a large US retrospective analysis
comparing performance measures before and after the introduction of combined 2D+DBT screening
has recently reported a 29% increase in cancer detection rate.140 Our modest improvement in sensitivity
reflects the selection bias in our method of case collection. Our data set comprised 85% of cases from
women recalled for abnormalities seen on the 2D screening, with a high proportion of cancer cases,
and this approach was considered to be the most appropriate at this stage in the evolution of DBT
technology when few clinical studies had been published. Thus, we may have underestimated the
contribution of DBT, since these cases had already been detected by 2D mammography. We have not
included cases where DBT demonstrated cancers from a screening cohort.
By using assessment cases for this study we effectively used 2D imaging to find all the cases in 100%
of the screened women. When we used 2D+DBT in the 5% of the women recalled from screening,
the readers were, in principle, able to find all the cancers identified as suspicious lesions in 2D for the
whole population. As for cancers only detectable by DBT, they could find these only in the 5% recalled.
Therefore, we have not used DBT in the other 95% that were not recalled. Thus, there may be 20 times
as many cancers detectable only by DBT in the whole screened population. In this study the sensitivity
improvement using 2D+DBT was only 2%. In actual screening we can expect up to 20 times more of this
type of cancer, leading to up to a 40% increase in cancer detection for 2D+DBT compared with 2D.
This calculation shows that, when one takes account of the method of case selection, the sensitivity
improvement found here is consistent with those published for screening,19,66,140 where increases of about
25–40% have been reported. Almost all previous non-screening studies are also affected by such case
selection issues.
Another possible explanation for the lack of improvement in sensitivity is that the addition of DBT may
have had minimal impact on the performance of this group of experienced, high-volume film readers.
The 19% significant improvement in specificity that we observed with 2D+DBT compared with 2D alone
would be consistent with published studies that highlight the potential of screening with 2D+DBT
to reduce false-positive recall rates. Nevertheless, the inherent selection bias in our study data set could
result in an overestimate of the true impact of DBT on specificity. Reductions in recall rate ranging from
15% to 42%59,60,138–140 have been reported using 2D+DBT in screening compared with 2D alone.
The magnitude of the decrease is likely to vary depending on the recall/arbitration policy in practice,
background recall rate and reader experience. Our study, similar to the Oslo19 and STORM66 trials,
was conducted with experienced readers from screening programmes with a generally low recall rate.
Although a greater impact of DBT on recall rate may be expected in the USA, where recall rates are often
higher than in the UK or Scandinavia, the largest published study to date140 reported a more modest
15% reduction in recall rate after the introduction of DBT. Since our study was not a screening trial, it is
difficult to predict the degree of improvement in sensitivity or specificity that could be expected in a
screening environment.
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In comparisons between studies, other methodological differences in study design that could confound
the interpretation of results should also be noted. Our study, similar to the Oslo19 and STORM66 trials,
used paired comparisons of 2D and 2D+DBT data from the same cases whereas other studies59,60,138–140
compared data from different cohorts of women before and after the introduction of 2D+DBT screening.
Differences in reading protocol could also impact on the interpretation of results. For example, our study
randomised the 2D and the 2D+DBT images for reading by different readers. In the Oslo trial,19 cases
were randomised for reading by 2D or 2D+DBT and adjusted for reader-specific performance, and,
in the STORM trial,66 cases were sequentially read, first with 2D and then 2D+DBT, by two readers.
The multicentre Friedewald study140 probably provides the most pragmatic evidence to date of the impact
of combined 2D+DBT in screening practice, but extrapolation of its generalisability to the UK and other
European screening programmes, where independent double reading is standard, is limited.
The inclusion of FH cases was intended to provide a cohort of younger women to examine whether or not
the addition of DBT to this group would be advantageous. Theoretically, this group could have given some
insight into the use of DBT in a screening setting, although it is recognised that this cohort was not
representative of the current UK NHSBSP screening population. However, we were unable to perform
a separate formal analysis for this cohort using the initial reading information. We accrued 1040 FH cases,
including two cancer cases. We were concerned that the reading protocol during case collection would
be difficult to apply rigorously. Hence, readers may not have provided an unbiased evaluation of 2D and
then 2D+DBT in the initial prospective data collection aspect of the study to permit evaluation of the
impact of DBT on reader performance.
The improvement in specificity for 2D+DBT compared with 2D alone was observed irrespective of
mammographic density, age, tumour size and dominant radiological feature and in both invasive cancers
and DCIS, as noted previously,16,59,60 and indicates the potential of integrated DBT to improve specificity
by allowing readers to avoid recalling false negative cases. In agreement with published studies,17,45,141
ROC analysis demonstrated a significant increase in diagnostic accuracy for 2D+DBT compared with 2D
alone and was most likely attributable to the marked improvement in specificity.
Planned subgroup analyses indicated that there was better sensitivity of 2D+DBT than 2D alone for
the detection of grade 2 invasive cancers, for 11- to 20-mm invasive cancers, and for lesions where the
dominant radiological feature was categorised as distortion or ASD. One explanation might be that small
grade 2 invasive cancers are slightly less likely than grade 1 cancers to show as masses. The addition of
DBT to 2D for cancers > 20mm appeared to have little impact, but ideally a screening programme would
detect invasive lesions smaller than 20mm, so this supports addition of DBT to a 2D examination. It has
been shown in other studies that the use of DBT is more advantageous for lesions with mass, rather than
microcalcifications, as the main radiological feature.17,43,44
One concern is that the addition of DBT will increase the detection of benign lesions such as radial scars and
complex sclerosing lesions,142 resulting in an increase in false-positives and an increased negative biopsy
rate. However, these drawbacks should be outweighed by the increase in cancer detection rate. Another
concern is that DBT will detect a higher percentage of grade 1 and 2 cancers than 2D mammography.
Tomosynthesis facilitates detection of stellate cancers of grades 1 and 2, as these tend to have greater
desmoplastic reaction resulting in more spiculate lesions than grade 3 cancers. This appears to be the
case from one study60 reporting the grade of cancers detected using the two techniques, 2D alone and
2D+DBT, but is not supported by results from another.19 These are the only two studies we found that
have published these data. It would be useful to have a breakdown of cancer grade from other large
studies such as Friedewald et al.140 and STORM66 for comparison before any conclusions can be made.
One notable observation from recent studies19,66,140 was the preferential increase in the detection of
invasive cancers with detection of DCIS unchanged. Since overdiagnosis/overtreatment of low-grade DCIS
is frequently quoted as one of the ‘harms’ facing breast screening programmes, confirmation of these
results in other trials with DBT would provide additional evidence in support of DBT as a screening tool.
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We did observe a significant improvement in sensitivity with 2D+DBT in women aged 50–59 years and for
women with breast density ≥ 50%. As young women are more likely to have high breast density and the
improvement of sensitivity for older women is a strong indicator for younger women, these observations
are of relevance when considering an extension of the UK screening programme to women younger
than 47 years.5,14,81,115 Increased breast density has been shown to be one of the strongest independent
predictors of breast cancer risk and accurate reproducible methods for the measurement of breast density
are being developed and validated.93 The results of our breast density substudy indicated that there was
a high degree of variation in the observed density scored by the image readers, whereas the two
commercially available software packages appeared to provide a more reliable assessment of breast density
when their output is compared with that found elsewhere in the literature.131,134 Although the software
packages had good agreement in the assessment of overall breast volume, they clearly implemented
different algorithms for the measurement of fibroglandular breast volume and at high breast densities the
correlation was less robust. We confirmed that there is a strong relationship between volumetric density
and increased risk of breast cancer. However, this is probably an underestimate as only cancer cases
detected at screening were included. Further analysis of interval and subsequent round cancers would
provide a truer estimate of breast cancer risk associated with density. The controversy in the USA over
mandatory reporting of breast density120 highlights the need for further research in this area, as noted by
Assi et al.93 At present, there is no reference standard for the measurement of breast density but
development of an accurate and reproducible method of breast density measurement will be required if it
is to be used to assess breast cancer risk and identify groups of women most likely to benefit from shorter
or longer screening intervals.
In May 2013, the FDA approved new software for the creation of a synthetic 2D image (C-View) from DBT
images based on data from a non-inferiority trial comparing the performance of synthetic 2D+DBT with
DBT alone. Our study design allowed comparison of the diagnostic performance of synthetic 2D+DBT
with both 2D and 2D+DBT imaging. This comparison is of clinical relevance, since current evidence
favours the use of DBT as an adjunct to 2D mammography rather than a stand-alone imaging modality.64
There was no significant difference in sensitivity between synthetic 2D+DBT and 2D alone, but specificity
was significantly higher. In comparison with 2D+DBT, there was no significant difference in sensitivity or
specificity for synthetic 2D+DBT. Subgroup analysis suggested that synthetic 2D+DBT, similarly to
2D+DBT, showed better sensitivity for the detection of 11- to 20-mm invasive cancers than 2D alone.
However, synthetic 2D+DBT was not as good as 2D or 2D+DBT in the detection of microcalcifications
and DCIS of size 11–20mm (where the dominant radiological feature is likely to be microcalcifications).
Only a few studies have been published to date on the performance of synthetic 2D. Although Gur et al.70
reported lower sensitivity but comparable specificity for synthetic 2D+DBT compared with standard
2D+DBT, two recent studies using the same version of the C-View software as our study, Skaane et al.78
and Zuley et al.,143 demonstrated comparable performance. Inferior performance of synthetic 2D images
from a prototype GE Healthcare (subsidiary of General Electric, Little Chalford, Buckinghamshire, UK) DBT
system was reported by Locatelli et al.,144 limiting its use for research purposes at present. Hologic have
produced a computer-aided detection algorithm for identification of microcalcifications which may improve
reader performance (Dr Susan M Astley, Department of Imaging Science and Biomedical Engineering,
University of Manchester, 2014, personal communication) but to date there are no published data.
In addition, coregistration of synthetic 2D and DBT images on the workstation could also improve
image interpretation.142
An advantage of our reading study was that there were sufficient numbers of cancers to test sensitivity
and specificity in each of the subcategories. The distribution of cancer cases in terms of invasion, size,
grade and lymph node status was similar to that found in the UK screening programme. Our study
involved 26 high-volume readers with variable years of experience and included radiologists, breast
physicians and advanced practitioner radiographers. This reflects the pragmatic current practice in UK
screening centres. In addition, three readers, each from different sites, were randomly assigned to read the
same case independently in one of the three reading arms, reducing the risk of individual reader bias.
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The major limitation of the study was that the study data set was primarily cases that had a
mammographic abnormality identified by 2D imaging. Thus, the ratio of cancer cases to normal cases
was higher than would be encountered in population screening where there is a ratio of 1 : 150–200;
therefore, the interpretation of results may not be applicable to those obtained in a screening
environment. In addition, the retrospective reading design meant that the readers knew that their reading
decision had no clinical implications and there may have been less concern with the consequence of
missing a cancer.
At the start of the trial we invited readers to undertake a DBT-only test set reading to ascertain variability
in reader performance and whether or not this changed over the duration of the trial following exposure
to reading with DBT. The reader test set study suggested that increased experience of reading with DBT
had little effect on reading performance but further analysis of individual reader performance from the
retrospective reading study will be undertaken. The reader study highlighted various aspects of reader
performance that require further research in terms of inter-reader and intersite variations in operating
point. The impact of longer reading times with DBT16,19,40,46,68 needs to be considered if DBT is to be
incorporated into the workflow of the screening programme.
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Chapter 7 Conclusions and future research
A lthough our study was in agreement with recent published studies in demonstrating that 2D+DBTperformed better than 2D alone in terms of specificity, we were unable to demonstrate the same
significant increase in sensitivity for 2D+DBT reported in these studies in our retrospective reading study.
Our study design clearly limits estimation of the impact of DBT on diagnostic performance and
extrapolation of our results to a screening population. Our method of case selection of index test cases
meant that the relative benefit of DBT on sensitivity has been underestimated, since these cases have
already been detected by 2D screening. Similarly, this data set is likely to have overestimated the impact
of DBT on specificity.
In our analysis, combined 2D+DBT imaging was shown to be more effective than 2D alone across all
age groups and breast densities, particularly for women aged 50–59 years and for breast density ≥ 50%.
If this effect was translated to population screening practice it would be advantageous to the planned
age extension of the NHSBSP for younger women who have denser breast tissue and to screening
mammography of the younger cohort of FH women. The potential of combined 2D+DBT imaging
to reduce the burden of false-positive recalls and associated diagnostic assessments would also benefit
screening programmes. Although this study was not designed to assess DBT in the diagnostic and
assessment setting, improved visualisation of benign and malignant features using DBT could reduce
the need for additional ultrasound, MRI or supplemental mammographic imaging.39–42
The screening population would also benefit if some of the anxiety and stress associated with breast
screening from unnecessary recalls and additional testing could be reduced.
Longer-term outcomes, as measured by interval cancer rates, will be of importance, since
subsequent-round screening with DBT would be unlikely to show a similar magnitude of improvement in
sensitivity. However, it could be expected that earlier detection of small invasive cancers would translate
into improved clinical outcomes.
Combined 2D+DBT imaging has been approved for screening in the USA and recently published studies
indicate that there is convincing evidence of a clear incremental benefit in invasive cancer detection with
the use of DBT. An American College of Radiology statement (22 July 2014) noted:
While there is strong evidence that tomosynthesis will have an important role in breast imaging,
further studies are needed to assess tomosynthesis’ relationship to long-term clinical outcomes,
including reduced mortality. It will also be important to learn which subgroups of women might
benefit most from these exams.145
While we recognise that additional information on the performance of DBT is required, the accepted ‘gold
standard’ of a randomised controlled trial (RCT) comparing 2D and 2D+DBT would be time-consuming
and expensive, and could delay implementation of a key imaging technology in screening by 5–7 years.
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Future research
l Since no formal cost-effectiveness/cost–benefit evaluations have been published, we suggest that
the feasibility and practicalities of implementing DBT into the workflow of a UK screening setting should
be evaluated. This should include a cost-effectiveness evaluation or modelling. This should also include
evaluation of the additional costs (e.g. upgrading equipment), providing information technology (IT)
support for image archiving, connectivity to PACS and IT systems, increased reading time and potential
benefits (e.g. increased cancer detection, particularly small invasive cancers, reductions in false-positive
recalls, additional diagnostic testing, and reduction in interval cancers).
l For combined imaging with 2D+DBT to be implemented in screening, the use of synthetic 2D
to minimise radiation exposure would be advantageous. The overall non-inferiority of synthetic
2D+DBT to 2D alone, shown in our study and in the publications of Skaane et al.78 and Zuley et al.,143
would justify use of this imaging combination in a RCT in a screening setting. However, before synthetic
2D+DBT could be recommended for screening, further comparative work with synthetic 2D and 2D
alone should be undertaken; for example quantifying the effect on sensitivity and specificity for lesions
with different radiological appearances, of different pathological types (e.g. DCIS, invasive, different
grades of tumour) and in different types of breast (e.g. > 50% density).
l It is important to note that the majority of published studies have utilised the Hologic DBT system.
Apart from some reading studies, relatively little literature exists for other commercially available DBT
systems. Therefore, more information is required from screening studies with other DBT systems
to verify the improvements in sensitivity and specificity shown by the Hologic system. This could be partly
achieved by modelling using simulated lesions and observer studies such as OPTIMAM (Optimisation
of breast cancer detection using digital radiograph technology).146
l Comparison should be made with 2D on the size, grade, and type of cancers detected by DBT,
for interval cancers and for cancers detected in the subsequent screening round, where we would
not expect the same degree of improvement in the detection of invasive cancers.
l We would recommend prognostic modelling on existing data sets of screen-detected and interval
cancers to predict the outcome of cases and projected impact on breast cancer mortality. This could
be achieved using, for example, the Nottingham Prognostic Index.147
l Mammographic density is one of the major risk factors for breast cancer and has the potential
to be incorporated into strategies for personalised risk prediction and screening guidelines. For example,
younger women with dense breasts, for whom standard 2D mammography is less effective, could
benefit more from screening with DBT, and recommendations to customise breast screening frequency
for women with different breast cancer risk profiles could also be made. These require development
of a validated method of assessing breast density.
l Further research is required into the ability of DBT to discriminate between early aggressive cancers
and slow-growing DCIS to address any concerns about DBT contributing to overdiagnosis.
CONCLUSIONS AND FUTURE RESEARCH
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Appendix 1 Participant information sheet for
women recalled for assessment
A Comparison of TOMosynthesis with Digital MammographY in
the UK Breast Screening Programme (the TOMMY trial)
You are being invited to take part in our research study. It is important for you to understand why
the research is being done and what it will involve. Please take time to read this information sheet carefully
and decide whether or not you wish to take part. One of our research team will answer any questions
you may have about the study.
What is the purpose of the study and why have I been chosen?
Mammography (breast X-ray) is undertaken to detect breast cancer. Tomosynthesis is a new method
of obtaining high-quality images that uses digital X-rays and a computer to generate three-dimensional
(3D) images of the breast.
In standard two-dimensional (2D) breast X-rays, some abnormalities may be missed at screening because
they are hidden by overlapping normal breast tissue. In addition, overlapping normal tissues of the breast
may show changes that raise concern. This leads to recall for assessment and further investigation,
and can generate unnecessary anxiety and stress. Preliminary studies have suggested that tomosynthesis
has advantages over standard 2D mammography by decreasing the problem of overlapping tissues.
This enables the structures of the breast to be seen more clearly.
You have been invited to take part in this research because you have been recalled for further assessment
following routine breast screening. The purpose of this study is to compare the accuracy of tomosynthesis
and standard mammography in the diagnosis of breast abnormalities found at breast screening.
Do I have to take part?
No, it is up to you to decide to participate in the study. If you do decide to take part you will be asked
to sign a consent form. You will be given this information sheet and a copy of the consent form to keep.
You are free to withdraw at any time, without giving a reason. This would not affect the standard of care
you receive.
What are the alternatives for diagnosis or treatment?
The standard procedure for patients who, like yourself, are recalled for further assessments is to have
additional mammographic imaging, ultrasound and needle biopsy if needed. You will still undergo this
assessment if you decide to participate in this study.
What will happen to me if I take part?
If you agree to take part in the study, you will have a standard 2D mammogram (the same as your breast
screening mammogram) and tomosynthesis imaging in addition to any other routine test like ultrasound
or biopsy during your visit to the clinic. Taking part in the study will add five to ten minutes of time to your
clinic visit.
Design of the study
We aim to conduct the study in six NHS Breast Screening centres in order to recruit a total of
7000 women. This will provide sufficient data to compare the accuracy of the two imaging techniques.
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What will happen to the additional images obtained during the study?
If tomosynthesis provides any additional information, this will be used to decide your treatment.
The tomosynthesis images will be kept on a computer system along with the standard mammogram
as part of your medical record. Copies of the tomosynthesis and standard mammography images from
each centre will be sent to researchers at a different study centre for independent comparison of the two
types of images. Any information about you which is sent to another centre will have your name and
address removed and replaced by a unique study number known only to the study research team.
What do I have to do?
If you wish to take part in the study we will ask you to sign a consent form when you attend your
clinic appointment. The radiographer will explain the tomosynthesis and the standard mammogram
examinations. This means you will have a further chance to change your mind if you then find you
do not wish to proceed with the tomosynthesis.
Will my taking part in this study be kept confidential?
All information which is collected about you during the course of the research will be kept strictly
confidential and in accordance with the Data Protection Act 1998. All patient information will be stored
securely on password protected computer databases or in locked filing cabinets. Information held by
the NHS and records maintained by the NHS Information Centre and the NHS Central Register may be
used to help contact you and follow-up your health status. Any information about you which leaves the
hospital will be identified by a unique study number.
If you join the study, some parts of your medical records and the data collected for the study may be
looked at by representatives of regulatory authorities to check that the study is being carried out correctly.
All staff will have a duty of confidentiality to you as a research participant. Nothing that could reveal your
identity will be disclosed outside the research site.
We will include information regarding your participation in the study in our letter to your general
practitioner following your clinic visit unless you instruct us otherwise.
What will happen to my data?
With your permission, images and data from this study will be used by other researchers to improve
the technology used to process and read mammograms and help us improve our understanding of breast
cancer. This information may be sent to a country outwith the European Economic Area. The information
will be kept strictly confidential. Your personal information will be removed and no one will be able
to connect you to the data.
Expenses
There are no payments or reimbursements for participating in this study as you will not be required to
make any additional visits.
Possible disadvantages and risks of taking part in the study
Most women experience minor or moderate discomfort during an X-ray mammography examination.
The tomosynthesis examination will be taken at the same time as the standard mammogram so there
should be no greater discomfort.
Women who are recalled to the clinic often have additional X-ray mammography. The tomosynthesis
examination involves an additional dose of radiation to the breast tissue. Participation in the study would
be equivalent to having two mammograms in a row. This has been considered by radiation protection
advisors and is not considered to be a significant risk to health. (The radiation dose of a mammogram
is equivalent to a few months exposure to natural background radiation).
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Side effects of tomosynthesis
The additional radiation dose has been discussed above (see Possible disadvantages and risks of taking part
in the study). No other potential side effects are known.
What are the possible benefits of taking part?
The tomosynthesis examination may provide more accurate judgement on whether or not an abnormality
is a cancer and it may be better at detecting very small or subtle cancers.
In the future, fewer women may need to be recalled for further tests due to ‘false alarms’.
Women in the study will benefit by having their mammograms looked at by additional specialists
at another breast screening centre. There is a small chance (1%) that they could detect an abnormality
that was missed at the assessment clinic. If this happens you would be invited back to your screening
centre for re-assessment.
We hope that the study will provide useful information for the NHS Breast Screening Programme.
What happens if there is a problem?
If you have a concern about any aspect of taking part in this study, you should contact the trial
coordination office (xxxxx xxxxxx) or the Patient Advisory Liaison Service (PALS) on xxx xxxx xxxx.
If you are harmed as a result of your participation in the study, due to someone’s negligence, then
you may have grounds for legal action but you may have to pay for it.
What if relevant new information becomes available?
Sometimes during a research project, new information becomes available about the diagnostic equipment
that is being studied. If this happens, the research team will consider whether any changes should be
made to the research method.
What happens when the research study stops?
In line with Good Clinical Practice guidelines, at the end of the study, your data will be securely archived
for a minimum of 15 years. Arrangements for confidential destruction will then be made.
What will happen to the results of the research project?
The results of the study will be published in medical journals and will be available at your local breast
screening centre.
Who is organising and funding the research?
The TOMMY trial is funded through the Heath Technology Assessment (HTA) Programme, part
of the Department of Health (www.hta.nhs.uk). The Department of Radiology, University of Cambridge
will undertake the day-to-day running of the trial, under the supervision of Professor Fiona Gilbert.
The University of Cambridge will act as Sponsor for the study and will be responsible for the governance
of the trial.
This study has been reviewed and given favourable opinion by the Scotland A Research Ethics Committee.
Thank you, we hope you will agree to take part in this study.
If you have any questions or would like any more information please contact xxxxx xxxxx by
phone xxx xxxxxxx or contact the TOMMY trial office (Tel: xxxxx xxxxxx;
email: xxxxxxxxxxxxxxxxxxxxxxx).
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Appendix 2 Participant information sheet
for moderate-/high-risk women as a result
of family history
A Comparison of TOMosynthesis with Digital MammographY in
the UK Breast Screening Programme (TOMMY trial)
You are being invited to take part in our research study. It is important for you to understand why
the research is being done and what it will involve. Please take time to read this information sheet carefully
and decide whether or not you wish to take part. One of our research team will answer any questions
you may have about the study.
What is the purpose of the study and why have I been chosen?
Mammography (breast X-ray) is undertaken to detect breast cancer. Tomosynthesis is a new method
of obtaining high-quality images that uses digital X-rays and a computer to generate three-dimensional
(3D) images of the breast.
In standard two-dimensional (2D) breast X-rays, some abnormalities may be missed because they
are hidden by overlapping normal breast tissue. This is a particular problem in younger women because
their breast tissue is more dense. In addition, overlapping normal tissues of the breast may show changes
that raise concern as they can mimic a cancer. This leads to further investigation, and can generate
unnecessary anxiety and stress. Preliminary studies have suggested that tomosynthesis may enable the
structures of the breast to be seen more clearly, even in dense breasts.
You have been invited to take part in this research because you are attending annual mammography
because of your family history. The purpose of this study is to compare the accuracy of tomosynthesis
and standard 2D mammography in the diagnosis of breast abnormalities.
Do I have to take part?
No, it is up to you to decide to participate in the study. If you do decide to take part you will be asked
to sign a consent form. You will be given this information sheet and a copy of the consent form to keep.
You are free to withdraw at any time, without giving a reason. This would not affect the standard of care
you receive.
What are the alternatives for diagnosis or treatment?
The standard procedure for patients who, like yourself, are at higher risk of developing breast cancer
is to have a standard 2D mammogram. You will still have a standard mammogram if you decide to
participate in this study.
What will happen to me if I take part?
If you agree to take part in the study, you will have tomosynthesis imaging in addition to a standard
2D mammogram. Taking part in the study will add five to ten minutes of time to your visit
to the screening centre.
Design of the study
We aim to conduct the study in six NHS Breast screening centres in the UK. In addition to recruiting
women with a family history of breast cancer we will also be inviting women who have had an
abnormality detected after routine breast screening to participate in the study. We aim to recruit a total
of 7000 women. This should provide sufficient data to compare the accuracy of the two imaging techniques.
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What will happen to the additional images obtained during the study?
If tomosynthesis provides any additional information, this will be used to decide if you need any further
tests. The tomosynthesis images will be kept on a hospital computer system along with your standard
mammogram as part of your medical record. Copies of the tomosynthesis and standard mammography
images from each centre will be sent to researchers at a different study centre for an independent
comparison of the two types of images. Any information about you which leaves the breast centre will
have your name and address removed so that you cannot be recognised from it. Participants in the study
will be allocated a study number known only to the research team.
What do I have to do?
If you wish to take part in the study we will ask you to sign a consent form when you attend your clinic
appointment. The radiographer will explain the tomosynthesis and mammogram examinations. This means
you will have a further chance to change your mind if you then find you do not wish to proceed with
the tomosynthesis.
Will my taking part in this study be kept confidential?
All information which is collected about you during the course of the research will be kept strictly
confidential and in accordance with the Data Protection Act 1998. All patient information will be stored
securely on password protected computer databases or in locked filing cabinets. Information held by
the NHS and records maintained by the NHS Information Centre and the NHS Central Register may be
used to follow-up your health status. Any information about you which leaves the hospital will be
identified by a unique study number.
If you join the study, some parts of your medical records and the data collected for the study may be
looked at by representatives of regulatory authorities to check that the study is being carried out correctly.
All staff will have a duty of confidentiality to you as a research participant. Nothing that could reveal your
identity will be disclosed outside the research site.
We will inform your general practitioner that you are participating in the study unless you instruct
us otherwise.
What will happen to my data?
With your permission, images and data from this study will be used by other researchers to improve
the technology used to process and read mammograms and help us improve our understanding of breast
cancer. This information may be sent to a country outwith the European Economic Area. The information
will be kept strictly confidential. Your personal information will be removed and no one will be able
to connect you to the data.
Expenses
There are no payments or reimbursements for participating in this study as you will not be required
to make any additional visits.
Possible disadvantages and risks of taking part in the study
Most women experience minor or moderate discomfort during an X-ray mammography examination.
The tomosynthesis examination will be taken at the same time as the standard mammogram so there
should be no greater discomfort.
The tomosynthesis examination involves an additional dose of radiation equal to that of a standard X-ray
mammogram. Participation in the study would be equivalent to having two mammograms in a row.
This has been considered by radiation protection advisors and is not considered to be a significant risk
to health. (The radiation dose of a mammogram is equivalent to a few months exposure to natural
background radiation).
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Side effects of tomosynthesis
The additional radiation dose has been discussed above (see Possible disadvantages and risks of taking part
in the study). No other potential side effects are known.
What are the possible benefits of taking part?
The tomosynthesis examination may provide more accurate judgement on whether or not an abnormality
is a cancer and may be better at detecting very small or subtle cancers.
In the future, fewer women may need to be recalled for further tests due to ‘false alarms’.
Women in the study will benefit by having their mammograms and tomosynthesis images looked
at by additional specialists at another breast screening centre at a later date. There is a small chance (1%)
that they could detect an abnormality that was missed at the assessment clinic. If this happens you would
be invited back to your screening centre for re-assessment.
We hope that the study will provide useful information for the NHS Breast Screening Programme.
What happens if there is a problem?
If you have any concerns about any aspect of taking part in this study, you should contact the trial
coordination office (xxxxx xxxxxx) or the Patient Advisory Liaison Service (PALS) on xxxxx xxxxxx.
If you are harmed as a result of your participation in the study, due to someone’s negligence, then
you may have grounds for legal action but you may have to pay for it.
What if relevant new information becomes available?
Sometimes during a research project, new information becomes available about the diagnostic equipment
that is being studied. If this happens, the research team will consider whether any changes should be
made to the research method.
What happens when the research study stops?
If the research study stops, this will not affect your attendance for annual breast screening.
In line with Good Clinical Practice guidelines, at the end of the study, your data will be securely archived
for a minimum of 15 years. Arrangements for confidential destruction will then be made.
What will happen to the results of the research project?
The results of the study will be published in medical journals and will be available at your local
breast centre.
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Who is organising and funding the research?
The TOMMY trial is funded through the Heath Technology Assessment (HTA) Programme,
part of the Department of Health (www.hta.nhs.uk).
The Department of Radiology, University of Cambridge, will undertake the day to day running of the trial,
under the supervision of Professor Fiona Gilbert. The University of Cambridge, will act as Sponsor
for the study and will be responsible for the governance of the trial.
This study has been reviewed and given favourable opinion by the Scotland A Research Ethics Committee.
Thank you, we hope you will agree to take part in this study.
If you have any questions or would like any more information please contact xxxxxxx xxxxx by
phone xxxx xxxxx or contact the TOMMY trial office (Tel: xxxxx xxxxxx;
email: xxxxxxxxxxxxxxxxxxxxxxx).
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Appendix 3 Consent form
CONSENT FORM 
 
A Comparison of TOMosynthesis with Digital MammographY in 
the UK Breast Screening Programme (TOMMY Trial) 
 
Please initial box 
 
1. I have read and understand the Information Sheet (Version 2.0  Dated 7th June 
2010 ) for the above study.  I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
2.  I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason. I understand that withdrawal would not 
affect my medical care or my legal rights. 
 
 
3. I give permission for authorised researchers and responsible individuals from 
regulatory authorities or from the NHS Trust or Board or University of 
Aberdeen to look at relevant sections of my medical notes if required. 
 
 
4. I agree to the transfer of my data and images out with the European 
Economic Area for use in future research. 
5. I understand that information held by the NHS, NHS Information Centre and 
NHS Central Register may be used to provide information about my health status 
 
 
6. I agree to my GP being informed of my participation in the study. 
 
 
7. I agree to take part in the above study 
 
 
Name of participant Date: Signature: 
Name of Person taking Consent: 
(if different from researcher) 
Date: Signature: 
Researcher: Date: Signature: 
 
White: Site File; Blue: Participant; Pink: Breast Screening Records 
 
DOI: 10.3310/hta19040 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 4
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
89

Appendix 4 Image management report
Design of the data transfer process
Early in the design of the trial it was decided to create a CDR to act as a hub for redistribution of the
images for the retrospective study and to provide a batch processing facility for the density analysis.
The CDR would also provide an archive for the total data set.
The CDR was designed and created at the University of Aberdeen on a HP DL385G7 running Red Hat
Enterprise Linux, Red Hat Inc, Raleigh, NC, USA and attached to network storage.
Hologic provided an existing anonymisation system (the Windows-based ‘HICS’ workstation) which
accompanied the commercial imaging equipment, and was installed at each site. Network transmission
was chosen to be the method of transfer for the anonymised images from each HICS to a central
repository. This satisfied the criteria of security, speed, flexibility, ease of use, reliability, data integrity
and robustness. Customised user software was written for the project to invoke the data transfer applications.
Network protocol
The protocol chosen was rsync-over-SSH (remote syncronisation over secure shell), with SSH providing the
security framework and rsync providing the data transfer framework; rsync is designed specifically for
mirroring large data stores over a network, and is highly optimised for such use. Both the protocols
themselves and, equally important, easily available software implementations, are mature, well proven and
highly regarded in the industry.
Ease of use
Ease of use was essential to managing the transfers at the sites, and this was achieved by arranging that
anonymised data sets simply needed to be deposited in a designated ‘Outgoing’ folder in order to enable
fully automatic upload, overnight, at regular prescheduled times. If the central data manager required
distributing images back to the sites, this was configured in a similar way on the central server.
During each scheduled ‘transfer slot’, following the upload, the images configured for sending were
downloaded automatically to the ‘Incoming’ folder at each site. All transfers were initiated from the
NHS-located sites, thereby avoiding any requirement to establish incoming connections to the New
National Network (N3).
Robustness and data integrity
The rsync protocol intrinsically provides both the ability to resume interrupted transfers and a guarantee
of end-to-end data integrity following a successfully completed transfer, owing to its use of rolling
checksums. In order to take full advantage of this, the wrapper application was designed to employ
a delay-and-retry algorithm if a network interruption is encountered, allowing transfers to resume
automatically following brief network downtime, while correctly terminating the transfer if downtime
exceeds a configurable threshold. This feature has proved invaluable, since the network path is long
and complex, and overall network reliability is not guaranteed, particularly when transferring large
numbers of data.
When a data transfer commenced, all data sets found in the ‘Outgoing’ folder were immediately moved
to a dated folder in the ‘Sending’ folder, and were not moved to the ‘Sent’ folder until all transfers had
completed successfully. This meant that if transfers were interrupted for any reason, when the application
was next run, the previous set of transfers ran to completion before any new transfers were started
and also ran to completion. These combined features provided a high degree of robustness and flexibility.
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Monitoring and accounting
Since data transfers necessarily took place automatically, overnight (to avoid network congestion during
working hours since large numbers of data are being transferred), it was essential to monitor transfers
and maintain accounting records. The wrapper transfer application therefore generated log files for every
transfer, and once the main transmitting and receiving transfers were completed, the log files also were
transferred to the central server, so that the logs might be examined both by the local staff at the sites,
and also by the central data manager. All transfers and logs were dated for ease of scrutiny.
Automated access credentials
In order to make automated access possible without human intervention (for overnight transfers),
automated management of credentials was required. The ability to do this is a standard feature of SSH,
and is based on public key cryptography. A unique key was installed at each site during installation
of the transfer application, thereby allowing each site to identify and authenticate itself when opening
a connection to start data transfer. On the CDR, SSH keys were stored securely on the local disk
(so access could not be interrupted by network problems), while the data folders were mounted from the
central storage resource. The SSH connections for the site accounts were ‘locked down’ so that
connections using any protocol other than rsync were refused by the CDR.
Main data store file system hierarchy
One issue which caused a certain amount of confusion within the project was the distinction between
the naming of the transmitted data set files and the internal R2ID numbers. The Hologic HICS anonymiser
replaces both the image accession numbers and the patient names and IDs with numeric IDs which simply
increment for successive anonymisations. However, the data set folder names (and individual filenames)
are based on the R2NUM (the anonymised accession number tag), not the R2ID (anonymised patient ID
tag). Since an accession is always unique, but a single patient may be scanned on a return visit, the
R2NUM and R2ID do not necessarily match (although for initial data sets they are likely to be the same).
When each image in a single data set is anonymised, the accession number is replaced by the generated
R2NUM, and both the Patient Name and the Patient ID are replaced by the generated R2ID. For this
reason, it was decided to add an additional level when creating the central data storage file system
hierarchy (since the internal R2ID is otherwise hidden). The hierarchy was SITENUM/R2ID/R2NUM.
Operation of the data transfer process
Relocation
Following the relocation of the chief investigator to Cambridge in 2011, it was agreed that image transfer
and storage of the images should be based in Cambridge.
In June 2012, Aberdeen distributed a new client software configuration that pointed the data collection
sites image transfers to Cambridge.
Storage and management of data
The CDR was reimplemented to the original design from the University of Aberdeen on the University
of Cambridge Clinical School of Computing Services virtual infrastructure [Ubuntu 12.04 LTS
(Canonical, London, UK) on VmWare (Palo Alto, CA, USA)] and network storage [(Network File System,
Oracle America, Inc., Santa Clara, California, USA) on NetApp filer with snap-mirroring on a 7-daily,
3-weekly rotation]. All trial image data (1.5 TB) acquired prior to the relocation were copied to the new
site on Linux Unified Key Setup encrypted external disk and verified against Message Digest 5 checksums.
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Local transfer
Initially images were transferred for quality assurance (QA) to the Cambridge Hologic SecurView
workstation in batches using the software storescu from the DCMTK DICOM toolset. Later, DICOM server
software (DCMTK dcmqrscp) was used to provide a ‘PACS query’ connection between the Cambridge
Hologic workstation and the CDR system for ad-hoc querying. The local network speed was
100Mb/second and was found to be inadequate for interactive case retrieval of the large data sets.
Issues involved in network connections
Transfers between Glasgow and Cambridge were hindered by the slow connection speed, around
87 kB/second up (Glasgow–Cambridge) and 750 kB/second down (Cambridge–Glasgow), about 20 times
and two times slower respectively than the other sites, which regularly achieved 1.5MB–5MB/second.
Most sites completed their transfers in a few hours in the middle of the night, but Glasgow had to start
immediately after office hours and spread the transfers out over the week. If for any reason a Glasgow
return transfer was missed or incomplete, it was difficult to catch back up again in time for the next.
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Appendix 5 Flow diagram indicating
management of image files
Trial site A Output from Selenia Dimensions
PACS SecurXchange SecurView reporting workstation
HICS
Patient identifiable data
removed from DICOM files
Secure data transfer
Processing facility for breast
density analysis CDR
Storage and archive
Distribution of copied image
files to sites for reading study
Secure data transfer
Trial site B SecurXchange
SecurView reporting
workstation
Retrospective reading
undertaken
Images deleted from
workstation
FIGURE 29 Flow diagram indicating the management of image files.
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Appendix 6 Quality control report on imaging
equipment
The NCCPM, which provides scientific and technical advice to the NHSBSP, was tasked with assuringthe performance of the imaging equipment involved in the trial. The purpose of the testing carried out
was to ensure that the dose and image quality on the seven systems employed for the trial complied
with existing standards84,148 for 2D mammography, to ensure that the imaging performances of all systems
in both 2D and tomosynthesis modes were well matched and to monitor the performance of the equipment
during the course of the trial. As well as physical testing of the imaging equipment, a survey was carried
out of clinical radiation doses delivered by each of the seven systems used in the trial. The results of the
QC testing showed that all imaging equipment met the relevant standards, the imaging performances of
the systems used in the trial were well matched and that they remained so during the course of the trial.
The knowledge and experience gained in carrying out the tomosynthesis QC testing for the trial has been
published149–153 and utilised in the preparation of UK and European DBT QC protocols.
Methods
The imaging equipment used for the trial consisted of seven Hologic Dimensions Tomosynthesis
mammography X-ray systems and the associated Hologic SecurView image display workstations, of which
there were eight at the start of the trial and a further two were added during the course of the trial.
For 2D imaging performance, the existing UK NHSBSP QC protocols84,148 were applied. In the absence
of any established protocols for tomosynthesis QC, it was necessary to devise suitable tests and phantoms
for the purpose, some of which were an extension of the 2D tests, and others novel tests to check aspects
of the quality of the reconstructed tomosynthesis images. The NCCPM provided test phantoms which were
specially manufactured for use by radiographers and physicists at each centre to ensure the comparability
of QC results between centres. The NCCPM prepared and provided QC protocols (see Appendices 15
and 16) to be used by radiographers and physicists at all centres during the trial. These protocols referred
to existing NHSBSP test protocols for 2D testing and included additional tests of tomosynthesis performance.
The NCCPM carried out rigorous initial testing at all six centres during the period July to December 2011,
before each of the seven X-ray systems commenced use in the trial. At this stage, efforts were made, with
the assistance of the installing X-ray engineers, to minimise differences between systems to ensure that
radiation dose and image quality was closely matched. Subsequent 6-monthly testing was carried out by
physicists contracted by NCCPM, who, in addition to providing their usual reports on the standard 2D
tests, returned the required 2D and tomosynthesis data and images to NCCPM for further analysis and
reporting. Radiographers at all centres carried out routine QC on a daily, weekly and monthly basis,
and returned data and images, on a weekly basis, to NCCPM for collation and analysis.
The QC testing carried out included tests of the image display equipment used in the retrospective reading
phase of the trial, as well as the X-ray equipment used to acquire the patient images.
In accordance with NHSBSP 0604, 84 clinical breast doses were calculated for a sample of 50 or more
patients imaged on each system.
Data from key measurements comparing the performance of systems at the start of the trial, and
subsequent 6-monthly testing, are presented, as well as an overview of the routine QC carried out by
radiographers and the results of the patient dose survey.
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Results
Dose
The MGD to the standard breast model, simulated with polymethyl methacrylate (PMMA) phantoms, was
assessed for conventional 2D imaging and tomosynthesis for a range of equivalent breast thicknesses.
The initial results for the seven systems are shown in Figure 30 and Table 26. The NHSBSP dose limits for
conventional digital mammography are also shown in Figure 30.
At 6-month intervals the MGD measurements were repeated. Table 27 summarises the overall averages
and ranges of values for all systems throughout the trial.
TABLE 26 Mean glandular dose to the standard breast and contrast-to-noise ratio averaged over the seven systems
and coefficient of variation, for conventional and tomosynthesis images
Equivalent breast
thickness (mm)
MGD for 2D images
MGD for
tomosynthesis
CNR for
2D images
CNR for
tomosynthesis
images
Mean (mGy) CoV (%) Mean (mGy) CoV (%) Mean CoV (%) Mean CoV (%)
21 0.60 3.4 0.89 3.1 10.9 2.9 29.1 2.5
32 0.84 2.4 1.04 3.5 9.9 2.3 22.2 2.8
45 1.17 2.4 1.43 3.9 9.0 3.5 18.9 2.8
53 1.41 3.2 1.87 4.2 8.4 3.4 18.5 3.5
60 1.98 1.6 2.29 3.8 8.6 3.3 17.2 3.7
75 2.69 2.1 3.39 4.3 8.3 3.0 14.8 4.7
90 3.03 2.5 4.25 3.6 6.7 4.7 11.3 4.3
CNR, contrast-to-noise ratio; CoV, coefficient of variation.
M
G
D
 (
m
G
y)
8
(a)
6
4
2
0
0 20 40 60 80 100
Equivalent breast thickness (mm)
Aberdeen BSC
Aberdeen FHC
Barts
Glasgow
Jarvis
Kings
Manchester
2D dose limit
M
G
D
 (
m
G
y)
(b)
8
6
4
2
0
0 20 40 60 80 100
Equivalent breast thickness (mm)
Aberdeen BSC
Aberdeen FHC
Barts
Glasgow
Jarvis
Kings
Manchester
2D dose limit
FIGURE 30 Mean glandular dose to the standard breast, for (a) conventional exposures and (b) tomosynthesis
exposures. BSC, Breast Screening Centre; FHC, Family History Clinic.
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The data in Table 27 show that the maximum deviation from the mean for 2D or tomosynthesis dose
measurements is 11%. To put these deviations into context, the remedial level for dose measurements
(NHSBSP 060484) is a change of 25% relative to baseline dose levels.
Contrast-to-noise ratio
Average contrast-to-noise ratio (CNR) measurements in conventional and tomosynthesis modes for the
seven systems involved in the trial are shown in Figure 31 and Table 26. Average CNR measurements in 2D
and tomosynthesis modes for the seven systems throughout the trial are shown in Table 28.
TABLE 27 Mean glandular dose measurements for all seven systems during the trial
Equivalent breast
thickness (mm)
Average
2D MGD
(mGy)
Minimum
2D MGD
(mGy)
Maximum
2D MGD
(mGy)
Average
tomosynthesis
MGD (mGy)
Minimum
tomosynthesis
MGD (mGy)
Maximum
tomosynthesis
MGD (mGy)
21 0.62 0.58 0.69 0.88 0.82 0.94
32 0.86 0.81 0.94 1.02 0.94 1.08
45 1.18 1.11 1.24 1.42 1.34 1.52
53 1.43 1.36 1.56 1.85 1.73 2.00
60 1.98 1.86 2.15 2.27 2.11 2.42
75 2.66 2.50 2.86 3.36 3.11 3.36
90 2.95 2.76 3.16 4.23 3.91 4.48
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FIGURE 31 Contrast-to-noise ratio for (a) conventional exposures and (b) DBT exposures. BSC, Breast Screening
Centre; FHC, Family History Clinic
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The data in Table 28 show a maximum deviation from the mean of 13% for 2D and 18%
for tomosynthesis, compared with a maximum deviation from the mean for the seven systems of 8%
at the initial testing. This is an acceptable spread in CNR measurements, given that the remedial level
for a single system is a 10% change from baseline measurements.
Tomosynthesis geometric distortion and interplane resolution
Tomosynthesis geometric distortion
For all systems, the height of best focus assessed at multiple positions within the image deviated
by no more than 1mm from that assessed at the centre of the chest wall edge. No distortion was
observed in the x and y directions. There was a 4% scaling error for all systems, but this had no impact,
as measurements of distance did not feature in the trial. There was no change in tomosynthesis
geometrical distortion measurements during the course of the trial.
Tomosynthesis z-resolution
The z-resolution for 1-mm aluminium balls was found to range between 9.8 mm and 12.0mm, with some
dependence on position within the image. The mean value was 10.8mm. No significant variation between
the systems or over time during the course of the trial was seen.
Detector modulation transfer function
Measurements of modulation transfer function (MTF) were made at the start of the trial. Only small
differences were seen between the seven systems. The MTF measurements are shown in Figure 32
and Table 29.
During the course of the trial, detector resolution for the seven systems was shown to have remained
unchanged by measurement of the threshold contrast detail detection, which included assessment
of small details.
TABLE 28 Contrast-to-noise ratio measurements for all seven systems during the trial
Equivalent breast
thickness (mm)
Average
2D CNR
Minimum
2D CNR
Maximum
2D CNR
Average
tomosynthesis
CNR
Minimum
tomosynthesis
CNR
Maximum
tomosynthesis
CNR
21 10.9 10.4 11.7 29.1 27.4 30.4
32 9.8 9.4 10.6 22.1 20.7 23.2
45 8.9 8.3 9.5 18.9 18.1 20.2
53 8.4 7.8 9.0 18.7 17.6 21.2a
60 8.4 8.0 9.1 17.1 16.0 20.3a
75 8.0 7.5 8.7 14.8 13.9 17.0a
90 6.4 6.0 7.3 10.9 10.4 12.0
a The higher maximum figures for tomosynthesis CNR are a result of some relatively high measurements from one centre
(Jarvis) during the second half of the trial, where installation of a software upgrade altered the apparent noise in the
reconstructed tomosynthesis QC images. Hologic provided assurance that this fault affected QC images only.
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Threshold contrast detail detectability
Figure 33 and Table 30 show the threshold gold thickness results for a range of detail diameters
for conventional and tomosynthesis images of a CDMAM test object (version 3.4, UMC St. Radboud,
Nijmegen University, the Netherlands). The results from initial testing on all systems are shown
and compared against the minimum acceptable and achievable values for conventional mammography
as defined in the NHSBSP protocol.84
Repeat measurements of image quality using a CDMAM test object on all systems every 6 months
demonstrated that there has been no significant change in image quality in either 2D or tomosynthesis
modes and that all systems continue to exceed the achievable image quality standard for
2D mammography.
Image display equipment
Testing of the performance of image display equipment was carried out at all centres by physicists
and radiographers as prescribed by NHSBSP protocols.84,148 Two of the workstations tested did fail the DICOM
greyscale standard as detailed in NHSBSP 0604,84 but these systems were recalibrated and reassessed
to ensure that they met the standard before commencement of the retrospective reading phase of the trial.
TABLE 29 Mean modulation transfer function measurements for the seven systems
Spatial frequency (mm–1) Mean MTF Coefficient of variation of MTF (%)
2 0.779 0.7
4 0.573 1.7
6 0.402 2.6
8 0.308 3.3
10 0.259 4.8
12 0.074 9.7
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FIGURE 32 Modulation transfer function measurements for the seven systems. BSC, Breast Screening Centre;
FHC, Family History Clinic.
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Quality control by radiographers
Daily, weekly and monthly tests of equipment performance were carried out by radiographers
on the seven systems used in the trial, in accordance with the trial protocol for radiographer QC
(see Appendix 17). All QC results were recorded electronically using a spreadsheet or database, and copies
were sent to NCCPM for checking. By carrying out daily QC, radiographers were able to check that X-ray
systems were functioning properly prior to use on patients and that no significant changes in dose or
image quality had occurred. As well as checking that no significant abnormal artefacts were evident in
images of plain PMMA, radiographers also examined reconstructed tomosynthesis images of a
1-mm-diameter aluminium ball, to ensure that there had been no change in its appearance, which might
TABLE 30 Average threshold gold thickness and coefficient of variation for 2D and tomosynthesis CDMAM images
Detail size (mm)
Threshold gold
thickness (µm) CoV (%)
Thickness
gold (µm) CoV (%)
Minimum
acceptable Achievable
0.10 0.655 8.3 1.277 6.7 1.680 1.100
0.25 0.175 4.0 0.218 2.3 0.352 0.244
0.50 0.075 6.8 0.095 2.3 0.150 0.103
1.00 0.040 12.3 0.043 8.9 0.091
CoV, coefficient of variation.
Th
re
sh
o
ld
 g
o
ld
 t
h
ic
kn
es
s 
(m
m
)
10.00
(a)
1.00
0.10
0.01
0.1 1.0
Detail diameter (mm)
Aberdeen BSC
Aberdeen FHC
Barts
Glasgow
Jarvis
Kings
Manchester
2D acceptable limit
2D achievable limit
(b)
10.00
1.00
0.10
0.01
Aberdeen BSC
Aberdeen FHC
Barts
Glasgow
Jarvis
Kings
Manchester
2D acceptable limit
2D achievable limit
0.1 1.0
Detail diameter (mm)
FIGURE 33 Contrast detail curves from each of the systems for conventional (a) and tomosynthesis (b) images.
BSC, Breast Screening Centre; FHC, Family History Clinic.
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suggest a failure in the tomosynthesis image reconstruction. Weekly QC images sent to NCCPM for
detailed analysis showed that dose and signal-to-noise ratio (SNR) in both conventional and tomosynthesis
images have remained stable and no clinically significant artefacts have been seen. The variation in dose
and SNR measurements for each system over time are shown in Figure 34. [The tomosynthesis SNR results
for one centre (Jarvis) doubled half way through the trial owing to a software upgrade necessitated by an
equipment breakdown. This led to a change in the calibration of the pixel values and hence SNR, which
has since remained stable. Subsequent checks have confirmed the manufacturer’s assertion that the
change is seen in QC images only, and that clinical image quality will not have been affected. This change
also affected the physicist’s measurements of CNR as described in pages 99–100.]
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FIGURE 34 Variation in 2D mammography and tomosynthesis dose and SNR from analysis of weekly QC images of
45-mm PMMA. (a) Weekly 2D mammography dose, (b) weekly Tomo dose, (c) weekly 2D mammography SNR and
(d) weekly Tomo SNR. BSC, Breast Screening Centre; FHC, Family History Clinic. (continued )
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Radiographers were also responsible for regular checks on the SecurView image display workstations
and reported to NCCPM that these checks were continued through to the end of the retrospective reading
phase of the trial.
Patient dose survey
Exposure data from each centre were analysed in order to calculate the estimated patient doses.
A summary of the data and calculated patient doses is presented. These results demonstrate that the seven
systems employed for the trial were set up to give doses that varied by less than 10% from the mean
in 2D and tomosynthesis modes. Although measurements of MGD to the standard breast model are
one-third higher for tomosynthesis than for 2D, estimates of clinical doses show that tomosynthesis doses
are on average only about 13% higher than 2D doses.
(c)
Date
90
80
70
60
50
20
10
40
30
0
17
/0
5/
20
11
16
/0
6/
20
11
16
/0
7/
20
11
15
/0
8/
20
11
14
/0
9/
20
11
14
/1
0/
20
11
13
/1
1/
20
11
13
/1
2/
20
11
12
/0
1/
20
12
11
/0
2/
20
12
12
/0
3/
20
12
11
/0
4/
20
12
11
/0
5/
20
12
10
/0
6/
20
12
10
/0
7/
20
12
09
/0
8/
20
12
08
/0
9/
20
12
08
/1
0/
20
12
07
/1
1/
20
12
07
/1
2/
20
12
06
/0
1/
20
13
05
/0
2/
20
13
07
/0
3/
20
13
06
/0
4/
20
13
06
/0
5/
20
13
05
/0
6/
20
13
SN
R
Jarvis
Barts
Kings
Glasgow
Aberdeen FHC
Manchester
Aberdeen BSC
(d)
Date
180
160
140
120
100
40
20
80
60
0
17
/0
5/
20
11
16
/0
6/
20
11
16
/0
7/
20
11
15
/0
8/
20
11
14
/0
9/
20
11
14
/1
0/
20
11
13
/1
1/
20
11
13
/1
2/
20
11
12
/0
1/
20
12
11
/0
2/
20
12
12
/0
3/
20
12
11
/0
4/
20
12
11
/0
5/
20
12
10
/0
6/
20
12
10
/0
7/
20
12
09
/0
8/
20
12
08
/0
9/
20
12
08
/1
0/
20
12
07
/1
1/
20
12
07
/1
2/
20
12
06
/0
1/
20
13
05
/0
2/
20
13
07
/0
3/
20
13
06
/0
4/
20
13
06
/0
5/
20
13
05
/0
6/
20
13
SN
R
Jarvis
Barts
Kings
Glasgow
Aberdeen FHC
Manchester
Aberdeen BSC
FIGURE 34 Variation in 2D mammography and tomosynthesis dose and SNR from analysis of weekly QC images of
45-mm PMMA. (a) Weekly 2D mammography dose, (b) weekly Tomo dose, (c) weekly 2D mammography SNR and
(d) weekly Tomo SNR. BSC, Breast Screening Centre; FHC, Family History Clinic.
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A summary of the patient data gathered at each centre is shown in Table 31.
Average MGD to 50- to 60-mm breasts for each unit are shown in Table 32, together with the MGD
to a 53-mm standard breast, simulated with 45-mm PMMA.
The patient dose measurements from all sites are shown in Figure 35. Also shown are the average
measurements from all sites of MGD to the standard breast model, as listed in Table 29.
A summary giving the range of clinical patient doses (minimum, maximum and mean MGD measurements)
for 2D and tomosynthesis views from patient data for all breast thicknesses at all sites is shown
in Table 33.
TABLE 32 Mean glandular dose to 53-mm standard breast and average MGD for oblique views of 50- to 60-mm
breasts
Centre
2D Tomosynthesis
MGD to 53-mm
standard breast (mGy)
Average MGD to 50- to
60-mm breasts (mGy)
MGD to 53-mm
standard breast
(mGy)
Average MGD to 50- to
60-mm breasts (mGy)
Aberdeen (FH) 1.41 2.02 1.88 2.13
Aberdeen
(screening)
1.36 1.87 1.80 2.04
Barts 1.39 1.62 1.92 2.11
Glasgow 1.41 2.16 1.79 2.10
Guildford 1.38 1.93 2.00 2.23
King’s College 1.47 2.15 1.80 2.02
Manchester 1.48 1.60 1.89 2.14
Average for
all sites
1.41 1.87 1.87 2.11
TABLE 31 Summary of patient dose data gathered from each centre
Centre
Number of patients
for whom dose data
was gathered
Period over which patient
dose data was collected
Mean age of
patient (years)
Mean
compression
force (N)From To
Aberdeen (FH) 56 15 December 2011 19 March 2012 45 94
Aberdeen
(screening)
106 19 December 2011 21 March 2012 57 109
Barts 74 12 July 2011 20 January 2012 55 80
Glasgow 99 30 August 2011 06 October 2011 57 119
Guildford 89 11 July 2011 25 August 2011 57 102
King’s College 105 6 September 2011 9 February 2012 57 91
Manchester 178 15 March 2012 30 April 2012 55 119
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Discussion
Performance testing of the imaging equipment employed for the trial ensured that the seven X-ray systems
were set up to give exposures that were closely matched, thus ensuring that there was no significant
variation in image quality between the systems. Thorough testing by physicists on behalf of NCCPM
at 6-month intervals ensured that there were no significant variations in imaging performance during
the course of the trial. More frequent tests carried out by radiographers at daily, weekly and monthly
intervals ensured that all systems were closely monitored during the trial so that any problems that could
have arisen were dealt with promptly. Tests carried out on image display equipment used to view clinical
images were tested regularly in accordance with NHSBSP protocols. The QC testing demonstrated that all
of the imaging equipment met, or exceeded, existing UK standards for 2D mammography, and that the
2D and tomosynthesis imaging performance of all systems were well matched.
The survey of patient radiation doses from each centre confirmed the findings of the physical QC
measurements, indicating that radiation exposures employed by the seven systems were well matched.
Conclusions
The QC program employed for the trial ensured that the imaging performance of all equipment employed
for the trial was well matched and met current applicable UK standards for 2D digital mammography,
both at the start and during the course of the trial. The experience gained has contributed to the
development of QC protocols for tomosynthesis in the UK and Europe.
TABLE 33 Summary of patient dose measurements at all sites, all views, all breast thicknesses
Mammographic views Minimum MGD (mGy) Maximum MGD (mGy) Mean MGD (mGy)
All 2D views 0.59 7.48 2.12
All tomosynthesis views 0.79 5.20 2.57
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FIGURE 35 Patient dose data from all sites (all views). Also shown are lines representing the average MGD to the
standard breast measured using PMMA for 2D and tomosynthesis exposures.
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Appendix 7 Prospective data collection form:
assessment
 
 
 
 
Key to code numbers 
Sign 0 None 
 1 Circumscribed Mass 
 2 Spiculated Mass 
 3 Micro-calcification 
 4 Distortion 
 5 ASD 
Suspicion 1 Normal 
 2 Benign 
 3 Probably Benign 
 4 Suspicious 
 5 Malignant 
Conspicuity 0 Not visible 
1 Barely visible 
2 Visible, not well seen 
3 Clearly visible 
Additional information from DBT Tick all that apply 
Lesion visibility 
 Lesion extent 
 Lesion characteristics 
Discrimination benign vs malignant 
 Other (please write comment) 
 
 
 
Lesion No:  
Sign 
0 - 5 
Suspicion 
1 - 5 
Conspicuity 
0-3 
 
Screen   MLO 
Films 
   
CC 
   
Assess. 2D MLO Clinic 
2D CC 
   
Slice 
No ↓ 
DBT MLO     
DBT CC     
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Appendix 8 Prospective data collection form:
family history
  
 
 
 
 
Key to code numbers 
Sign 0 None 
 1 Circumscribed Mass 
 2 Spiculated Mass 
 3 Micro-calcification 
 4 Distortion 
 5 ASD 
Suspicion 1 Normal 
 2 Benign 
 3 Probably Benign 
 4 Suspicious 
 5 Malignant 
Conspicuity 0 Not visible 
1 Barely visible 
2 Visible, not well seen 
3 Clearly visible 
  
 
 
 
 
 
Additional information from DBT 
(tick all that apply) 
 1 Lesion visibility 
 2 Lesion extent 
 3 Lesion characterisation 
 4 Discrimination benign vs malignant 
 5 Other (please write comment) 
 
 
 
 
Lesion No:  
 Sign 
0 - 5 
Suspicion 
1 - 5 
Conspicuity 
0-3 
 
2D MLO    
2D CC    
Slice No ↓ 
DBT MLO     
DBT CC     
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Appendix 9 Prospective data collection form:
pathology
Tumour Type (please tick) 
1 Invasive Ductal 3e Metastases 
 2 Invasive Lobular  3f Lymphoma 
 3a Medullary  3g Other 
 3b Mucinous  4 Lobular In Situ 
 3c Tubular  5 Ductal In Situ 
 3d Intracystic papillary  
Lymph Node Status(please tick) 
 1 Normal 
 2 < 4 nodes positive 
 3 >4 nodes positive 
 4 Not known 
*Coding for Hormones and HER status 
1 Positive 
2 Negative 
3 Unknown 
0 Not assessed 
 
Assessment Biopsy Score (please tick)
 1 Normal 
 2 Benign 
 3 Benign equivocal 
 4 Suspicious of malignancy 
 5a Malignant  non invasive /in situ 
 5b Malignant invasive 
 0 Not performed 
Tumour Grade (please tick)
 1 I 
 2 II 
 3 III 
 4 Unknown 
Hormone/HER-2 status Score Code* 
ER status Quick Score (0-8)   
PgR status Quick Score (0-8)   
C-erb-B2/HER-2 Status Grade (0-+3)   
Tumour Size (mm) 
DCIS only size (no invasive component)  
Invasive size  
Whole tumour size  
Baseline image measurement if neo-adjuvant chemotherapy  
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Appendix 10 Randomisation process for
retrospective reading study
RANDOMISATION PROCESS FOR RETROSPECTIVE READING STUDY 
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Appendix 11 Retrospective study data collection
form: two-dimensional
 
 
 
 
Suspicion 
1 Normal 
 
2 Benign 
 
3 Probably benign 
 
4 Suspicious 
5 Malignant 
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Appendix 12 Retrospective study data collection
form: two-dimensional and three-dimensional
 
 
4.Discrimination 
-2 DBT much poorer than 2D 
 
-1 DBT slightly poorer than 2D 
 
0 DBT equal to 2D 
 
+1 DBT slightly better than 2D 
 
+2 DBT much better than 2D 
 
5.Overall opinion 
-2 DBT much poorer than 2D 
 
-1 DBT slightly poorer than 2D 
 
0 DBT equal to 2D 
 
+1 DBT slightly better than 2D 
 
+2 DBT much better than 2D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please score items 1 to 5 by ticking the appropriate box: 
1.Suspicion 
1 Normal 
 
2 Benign 
3 Probably Benign 
 
4 Suspicious
 
5 Malignant 
 
2.Lesion visibility 
-2 Only seen on 2D 
 
-1 DBT poorer than 2D 
0 DBT equal to 2D 
 
+1 DBT better than 2D 
 
+2 Only seen on DBT 
 
3.Lesion extent 
-2 
DBT much poorer than 
2D 
-1 
DBT slightly poorer than 
2D 
 
0 DBT equal to 2D 
 
+1 
DBT slightly better than 
2D 
 
+2 
DBT much better than 
2D 
 
 
DBT MLO Slice no. 
 
DBT CC Slice no. 
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Appendix 13 Invitation letter for assessment
women
(To be printed on local headed paper)
Dear
You have been requested to attend an appointment at <<local centre>> for further investigation
of an abnormality detected on your recent breast screening X-ray examination (mammogram).
I am writing to let you know that <<local centre>> is currently taking part in a research study to evaluate
whether a new imaging technique could be more accurate than standard screening X-rays in detecting
breast abnormalities. We would like to give you the opportunity to participate in this study.
Information about the research study is included with this letter. If you agree to participate in the study
you will be asked to have an extra imaging examination at the assessment clinic, in addition to any other
routine diagnostic tests.
If you have any questions about the study please call <<local contact name>> at <<local centre>>
on telephone number <<xxxxx>> or contact the trial office on xxxxx xxxxxx.
Thank you for taking the time to read this information.
Yours sincerely,
Name of Local PI
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Appendix 14 Invitation letter for moderate- or
high-risk women as a result of family history
(To be printed on local headed paper)
Dear
You have been invited to attend your annual breast mammogram at <<local centre>>.
I am writing to let you know that <<local centre> is currently taking part in a research study to evaluate
whether a new imaging technique could be more accurate than standard screening X-rays in detecting
breast abnormalities. We would like to give you the opportunity to participate in this study.
Information about the research study is included with this letter. If you agree to participate in the study
you will be asked to have an extra imaging examination. Your results will be sent to you as normal.
If you have any questions about the study please call the research team at the <<local contact name>>
at <<local centre >> on telephone number <<xxxxx>> or the Trial Office on xxxxx xxxxxx.
Thank you for taking the time to read this information.
Yours sincerely,
Name of local PI
DOI: 10.3310/hta19040 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 4
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
121

Appendix 15 Letter to general practitioner
advising of trial participation
Dear Doctor Patient name(s)
The above patient(s) has consented to participate in the TOMMY trial at <<local centre>>.
The TOMMY (TOMosynthesis and MammographY) Trial is a comparison of Digital Breast Tomosynthesis
(DBT) and standard digital mammography in the NHS Breast Screening Programme. The study has been
funded by the Health Technology Assessment Programme and has received favourable ethical opinion
from the Scotland A Research Ethics Committee.
The purpose of the study is to compare the performance of DBT and standard mammography in diagnosis
of breast abnormalities. We aim to recruit 1000–1200 women locally over a 15–18-month period.
Women (age 47–73 years) who have been recalled for assessment after abnormal routine screening
mammography will be invited to participate. Women (age 40–49 years) with a family history of breast
cancer who are attending annual screening mammography will also be eligible.
For women giving written informed consent, a standard digital mammogram and DBT imaging
examination will be performed. Both sets of images will be reviewed independently to evaluate the relative
sensitivity and specificity of the two imaging techniques.
For further information please contact << local contact details>> or the Trial Coordination Office
(Tel: xxxxx xxxxxx or email: xxxxxxxxxxxxxxxxxxxxxxx).
Yours sincerely,
Local PI
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Appendix 16 National Co-ordinating Centre for
the Physics of Mammography tomosynthesis
commissioning protocol for the TOMMY trial
T he mammography equipment to be used in the TOMMY trial will be commissioned accordingto IPEM 89 and NHSBSP Equipment Report 0604, which cover the testing of conventional digital
mammography X-ray equipment and image display equipment. This protocol details the additional tests
which will be carried out, including newly developed tests for digital breast tomosynthesis systems.
For all tests the ‘Std Acq’ mode should be selected – not the enhanced mode as this increases the doses
delivered. Use fixed rather than flexible paddle.
Compressed breast thickness indication
Use blocks of PMMA of known thickness. Position on breast support table overhanging the chest wall edge
such that the back edge of the top block is 8 cm from the chest wall edge (thus allowing the paddle to tilt
slightly as it would during a clinical mammogram). Compress to 100 N and record the actual thickness and
the indicated thickness. Repeat for thicknesses of approximately 2 cm, 5 cm and 7 cm or 9 cm.
Reproducibility and homogeneity
Make 5 flatfield tomo exposures of large (24 × 30) 45-mm PMMA block with automatic exposure control
(AEC) in Autofilter mode at the beginning of testing, with the paddle and using the same compressed
breast thickness for all exposures to ensure selection of the same kV. Make a further exposure a few hours
later and/or at the end of testing. These are used to check stability of mAs and SNR (though a valid SNR
cannot be calculated for the Hologic Dimensions system due to the scaled pixel values), and also to check
for homogeneity and artefacts.
Also make flatfield tomo exposures as above in AutokV and Autotime modes (with kV manually selected
to match that for the Autofilter exposures) to ensure that the mAs at a given kV does not vary between
AEC modes. Also try a combo exposure in each AEC mode and check that the exposure factors for the 2D
and tomo exposures are not different from those obtained when making individual exposures.
During these scans measure tomo and scan times with a stopwatch. Tomo time begins when the expose
button is pressed and ends at decompression. Scan time begins at start of first X-ray exposure to end
of last X-ray exposure (measure this in Autofilter/Autotime AEC mode and in manual mode).
Polymethyl methacrylate dose and thickness compensation
The Hologic system chooses beam quality based purely on indicated compressed breast thickness which
is unfortunately in error when large PMMA blocks are compressed due to the paddle being prevented
from tilting as it normally would in clinical situation. PMMA doses and CNR measurements should
therefore be measured without spacers and the paddle positioned at such a height as to give the desired
compressed breast thickness (i.e. equal to the equivalent breast thickness for the thickness of PMMA on
the table). For 2 to 4-cm PMMA the top block may need to be moved forwards in order to allow the
paddle to come down far enough. PMMA dose measurements are combined with the thickness
compensation measurements.
DOI: 10.3310/hta19040 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 4
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
125
Tomo
Position ball phantom (15-mm PMMA containing 10-mm 100% glandularity ball) on top of a 5-mm sheet
of PMMA on the breast support table making up a total thickness of 20mm. Image using a flatfield tomo
scan in Autofilter AEC mode and record the kV and mAs. Repeat with additional thicknesses of PMMA
placed on top of the phantom and for each thickness position the paddle to give the appropriate indicated
breast thickness.
Conventional
Use 0.2-mm aluminium square on the midline 60mm from chest wall edge, sandwiched between two
10-mm plates PMMA. Image using flatfield conventional in Autofilter AEC mode. Repeat with additional
thicknesses of PMMA placed on top of the phantom and for each thickness position the paddle to give
the appropriate indicated breast thickness.
Repeat using local physics aluminium square and PMMA for comparison.
Tube output
Half-value layers (HVLs) and tube outputs are measured in conventional and tomosynthesis modes
with the paddle in the beam for the purpose of MGD calculations. The Monte Carlo simulations on which
MGD calculations are based were actually carried out with the paddle in contact with the ion chamber,
which increases the dose measured by a few per cent. For the TOMMY trial we have decided to use doses
measured with the paddle in contact with the ion chamber for both tomosynthesis and conventional MGD
so that the measurements are comparable. The dose with the paddle not in contact with the ion chamber
will also be measured so that the MGDs for conventional mammograms can be compared to those from
other systems measured in the usual way with the paddle not in contact according to the UK protocol.
Place steel or lead plate on breast support table to protect detector (should be a piece of ‘heavy wood’
labelled MIS in the room).
Position ion chamber at standard position on midline 4 cm from chest wall edge 10 cm above the table.
Position the paddle immediately above and in contact with the ion chamber. (It may be easier to put
the paddle in position first.) Position a collimator above the paddle close to the tube port such that the
light beam is collimated to the chamber. The HVL filters will be placed on top of this collimator.
Select 50mAs and measure the output and HVL for the clinical range of beam qualities in conventional
and tomosynthesis modes. The HVL should be measured using thicknesses of aluminium filters just below
and above the actual HVL.
For the tomosynthesis exposures use the ‘zero degree tomo’ setting (a series of short exposures without
rotation, dosemeter will need to be set to accumulation mode).
Record actual mAs (likely to differ slightly from setting) and dose reading, focus-to-chamber distance,
focus-to-table distance.
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Detector response, modulation transfer function, noise
power spectrum
These tests are to be carried out in conventional 2D mode only.
Detector response
Collimate beam to 10 × 10 cm centred on the midline 6 cm from the chest wall edge. Attach 2-mm
aluminium to the tube port. Remove grid and protect detector. Place ion chamber 6 cm from the chest
wall edge on the midline. Use 29WRh (same kV, target, filter as was selected automatically for 45-mm
PMMA). Measure doses for 6 dose levels ranging from 4 to 125mAs. Repeat measurements for lowest
dose to ensure repeatability. Remove ion chamber and protector and image using conventional flatfield
exposures for the same mAs values.
Modulation transfer function
Position MTF tool on table so that the middle of its edge passes through the midline 6 cm from the chest
wall edge at a slight angle (1.5–3 degrees) to a line either parallel or perpendicular to the chest wall edge.
Take image using 29WRh 100mAs For each orientation take two images with the MTF tool either side
of the line, giving four images in total.
Noise power spectrum
Take 4 images at each of 5 dose levels using 29WRh to give 0.25, 0.5, 1, 2, and 4 times a typical detector
dose (approximately 7, 14, 28, 56 and 112mAs).
Alignment
Alignment of X-ray beam with imaged plane at detector surface
Place sheet of white paper or card on table for better visibility and reduced slipperiness. Position rulers
(+ outwards) with edge of light beam aligned with zero. Two rulers at front and one on each lateral side.
At the back edge there is not enough space for a ruler so use another marker. An 18 × 24 sheet of PMMA
(maximum 5-mm thick) or something else not too attenuating is helpful to place on top to hold rulers
in place. Place strips of Gafchromic on top of rulers with line across middle aligned with zero on the rulers.
Expose using flatfield tomo, manual, 32 kV, 140mAs (two exposures to get enough blackening),
no paddle. To reduce size of image keep paddle holder as low as possible without casting shadow on
back part of image.
Missed tissue at chest wall edge
Position a 6-cm stack of PMMA aligned with front edge of table. Insert X-ray rulers at 0, 3, 6 cm above
table with zero aligned with front edge of PMMA/table. Expose with flatfield tomo under AEC control.
Geometric distortion
Place the geometric distortion grid on the breast support table with large slabs of PMMA on top to make
a total thickness of around 60mm. Bring paddle down to rest on top of the PMMA and image using
flatfield tomo Autofilter AEC setting. Repeat with the geometric distortion phantom in the middle of
and on top of the stack of PMMA. (If there is evidence of distortion in the images then further
investigation may be required at additional heights within the PMMA stack.)
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Z-resolution
Place large 5-mm sheet of PMMA on breast support table with Z-resolution phantom (5-mm PMMA
containing 6 × 1-mm aluminium balls) on top. Add a further 40-mm PMMA to make up the total thickness
to 50mm. Bring paddle down to rest on top of the PMMA and image using flatfield tomo Autofilter AEC
setting. Repeat with the Z-resolution phantom positioned approximately in the middle of the stack, and
again 5mm from the top of the stack.
Image quality
Position CDMAM aligned with the chest wall edge of the breast support table sandwiched between
2- × 2-cm PMMA and bring paddle down to rest on top of the PMMA. Check the image to ensure
that the edges of the CDMAM are within the image. Repeat to give a total of 16 images, moving the
CDMAM very slightly between exposures.
Tomo
Use flatfield tomo and manual setting to give the same kV and mAs (or as close as possible using either
Manual or Autotime AEC setting) as was selected automatically for tomo exposures of 5-cm PMMA
with the paddle at 6 cm.
Using the same settings also take 16 images of local CDMAM for comparison.
Conventional
Use flatfield conventional and manual setting to give the same kV and filter (31WRh) and mAs
(or as close as possible using either Manual or Autotime AEC setting) as was selected automatically for
conventional exposures of 5-cm PMMA with the paddle at 6 cm.
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Appendix 17 Radiographer quality control
for the TOMMY trial
The radiographer QC required for the TOMMY trial will be the NHSBSP-recommended tests for digitalmammography with four additional tests for tomosynthesis. The tests are listed below.
List of required tests
Monitors
Daily checks on acquisition and reporting monitors (NHSBSP 0702 section 2.1). Monthly test of reporting
monitors (NHSBSP 0702 section 2.2).
X-ray unit
Daily system check in conventional 2D mode (NHSBSP 0702 section 3.1).
*Daily system check in tomosynthesis mode.
Weekly CNR check in conventional 2D mode (NHSBSP 0702 section 3.2). Weekly uniformity check
in conventional 2D mode (NHSBSP 0702 section 3.3). Weekly image quality test in conventional 2D mode
(NHSBSP 0702 section 4).
*Weekly remote QC images in 2D and tomosynthesis modes.
Weekly detector flat field calibration (according to manufacturer’s instructions). Monthly thickness check
in conventional 2D mode (NHSBSP 0702 section 3.4).
*Monthly thickness check in tomosynthesis mode.
Monthly mechanical and safety function tests (NHSBSP 0702 section 7).
*Six-monthly geometry calibration for tomosynthesis (according to manufacturer’s instructions).
Repeat analysis (NHSBSP 0702 section 8).
(* denotes additional QC for TOMMY trial.)
Instructions for quality control tests
For the conventional 2D digital mammography tests, the instructions given in NHSBSP 0702 should
be followed. Further notes on some of these tests are included later in this document.
There are two additional tests required by Hologic which should be carried out according
to their instructions given in the Hologic Selenia Dimensions QC Manual. One of these is the weekly
flat field calibration for conventional 2D mammography, the other is the geometry calibration for
tomosynthesis systems.
Instructions for the other three additional tomosynthesis tests for the TOMMY trial are included later
in this document.
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Quality control equipment
It is expected that mammography centres taking part in the trial will already have the required equipment
for testing conventional digital mammography systems according to NHSBSP 0702.
Equipment for the manufacturer’s required QC (flat field and geometry calibrations) are supplied
with the system.
National Co-ordinating Centre for the Physics of Mammography supply a test phantom with which to carry
out the additional weekly remote QC tests, the images from which are sent to NCCPM.
Recording of quality control results
Conventional 2D QC should be recorded in the normal way as per local procedure. A weekly summary
of 2D local QC is also to be entered onto the spreadsheet provided and sent to NCCPM each week.
The spreadsheet also contains pages for the recording of the additional tomosynthesis tests. These pages
can be printed out and used as paper forms to collect the data on a daily basis, to then be copied into the
spreadsheet and sent to NCCPM each week. Where there is an existing digital QC spreadsheet in use,
the TOMMY spreadsheet may be grafted onto it to avoid unnecessary duplication in data entry.
Physics support
National Co-ordinating Centre for the Physics of Mammography intend to appoint a local mammography
physicist for each site to provide physics cover for the equipment used for the TOMMY trial. If it is not
possible to appoint a local TOMMY physicist then NCCPM will provide the required physics cover. Where
QC results fail remedial levels, and the problem is not resolved, then the TOMMY physicist should be asked
for advice before continuing to use the equipment for the trial. If the local TOMMY physicist is not
available then NCCPM should be consulted instead. In any event, NCCPM should be kept informed of any
problems that occur.
Quality control baselines and remedial levels
Baselines for conventional 2D tests will be set in the usual manner according to local protocol and remedial
levels will be set following recommendations in NHSBSP 0702. Baselines and remedial levels for the
tomosynthesis tests should be set in a similar manner using the provisional remedial levels quoted in
the table summarising remedial levels for all tests appended to this document. The TOMMY physicist should
be consulted if assistance is required in setting baselines and remedial levels. Once the baselines and
remedial levels have been set they should be sent to the TOMMY physicist and to NCCPM, so that they can
be checked and compared with those from other sites in the trial. If there is ever any need to alter any
baselines or remedial levels, the TOMMY physicist and NCCPM must be consulted. As experience is gained
in the testing of tomosynthesis equipment, NCCPM may decide to make changes to test methods or
remedial levels, and will inform all concerned.
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Reporting of quality control to the National Co-ordinating
Centre for the Physics of Mammography
Each week the following should be sent to NCCPM:
l The completed QC spreadsheet containing a summary of the 2D QC results and the tomo test records.
l The weekly remote QC images (not from SecurView or PACS):
¢ The tomosynthesis image of aluminium ball in PMMA.
¢ The tomosythesis image of plain PMMA.
¢ The 2D image of plain PMMA.
The weekly QC summary should be sent by e-mail to the e-mail address given below.
Quality control images need to be written to a CD/DVD directly from the acquisition workstation and sent
to NCCPM. We require raw tomosynthesis images which are not transferred to the PACS network or
SecurView workstation. These can only be written to CD or DVD using the acquisition workstation in the
X-ray room.
Instructions for downloading QC images to CD/DVD:
Open the weekly QC study and check that it contains the required QC images and not patient images.
(Obviously it is very important that no patient image is included as this would contravene data protection
laws). Put a blank CD or DVD in the drive and click on the ‘Export’ icon. Select destination ‘E:’ and start.
Only one study can be written onto each disc.
When the facility becomes available it is planned that QC images will be transferred from the acquisition
workstation to NCCPM via secure internet link.
Contact details for the National Co-ordinating Centre for the
Physics of Mammography:
Celia Strudley is the main contact for TOMMY QC, but if not available other staff should be able to help.
Address: NCCPM (Medical Physics)
Level B, St Luke’s Wing Royal Surrey County Hospital Guildford
GU2 7XX
Telephone: NCCPM office: xxxxx xxxxxx
Celia direct: xxxxx xxxxxx ext xxxx E-mail: xxxxxxxxxxxxxxxxxxxxxxxxxx
(This e-mail address will be monitored by NCCPM staff dealing with QC issues during the trial)
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Tomosynthesis quality control instructions
Daily system check in tomosynthesis mode
This test is an extension of the existing 2D daily system test, and the two would be most easily carried
out together.
Use the same PMMA block and compression paddle as are used for the daily 2D system test.
Place the PMMA on the breast support table.
This test should always be carried out with the paddle in the fixed position or carried out with the paddle
in the flexible position.
Compress to 100 N (or as near to as possible, 95–105 N is acceptable) Set the AEC sensor to position 2.
In addition to the conventional 2D Autofilter flatfield image, take a tomosynthesis Autofilter image
of the block. These two images may be taken as a combo exposure.
Record the following:
l compressed breast thickness
l kV
l mAs.
View the reconstructed image slices (not the projections) on the X-ray unit. While scrolling through
the tomosynthesis slices, look for any abnormal artefacts in the image, and record whether or not any
abnormality has been observed.
Enter all the recorded information onto the form/spreadsheet provided, and compare the mAs against
the remedial level. Where any remedial levels are exceeded, repeat the test to ensure that a mistake has
not been made.
If remedial levels are exceeded or abnormal artefacts are observed then contact the TOMMY physicist
for advice before continuing to use the equipment for patients in the trial. Any image containing abnormal
artefacts must be saved for investigation and a copy should also be sent to NCCPM.
(It is not possible to measure pixel values within a region of interest [ROI] in a reconstructed tomosynthesis
slice on the Dimensions AWS, so the calculation SNR or CNR values for tomosynthesis images is not
required for Radiographer QC.)
Weekly remote quality control images
Image of test object containing 1-mm aluminium ball in tomosynthesis mode
Place the 5-mm sheet of PMMA containing the 1-mm aluminium ball between the two 22.5-mm thick
sheets of PMMA on the breast support table. The aluminium ball is located on the midline 6 cm from one
of the long edges of the sheet – this long edge should be aligned with the chest wall edge of the table.
Use the large 24 × 29 compression paddle (in fixed mode). Compress to 100 N (or as near as possible,
95–100 N is acceptable) Set the AEC sensor to position 2.
Take a flatfield tomosynthesis image with the AEC in Autofilter mode.
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View the reconstructed image slices (not the projections) on the acquisition workstation in the X-ray room.
Press the ‘Actual pixels’ button to bring the image into full resolution, and using the wheel scroll through
the image. The aluminium ball should be visible as a spot somewhere between slice numbers 20 and 30.
Find the slice at which the image of the ball appears sharpest and least distorted and record that slice
number. The ball may appear fairly sharp over a range of 3 to 5 slices – record a slice number
in the middle of the range.
Check that the ball appears sharp and circular in this slice. Record whether or not this is so.
Above and below the slice in which the ball appears sharpest the ball will appear to become elongated
in the vertical direction (parallel to chest wall edge). Check that the appearance of this line is as normal
with no broadening, twisting, or otherwise abnormal appearance. Record whether or not the appearance
is as normal.
If any abnormalities are seen in the appearance of the ball in the reconstructed tomo image, contact
the TOMMY physicist for advice before continuing to use the equipment for patients in the trial.
Two dimensional and tomosythesis images of large plain PMMA block.
Place the two 22.5-mm thick sheets of PMMA on the breast support table. Use the large 24 × 29
compression paddle (in flexible mode).
Compress to 100 N (or as near as possible, 95–100 N is acceptable) Set the AEC sensor to position 2.
Take a flatfield combo image with the AEC in Autofilter mode. Display the 2D image on the monitor
and check carefully for artefacts.
Display the reconstructed tomo image on the monitor and scroll through the slices, checking carefully
for artefacts.
Record whether or not any abnormalities are seen. If any abnormalities are seen in either the 2D or the
tomo image, contact the TOMMY physicist for advice before continuing to use the equipment for patients
in the trial.
Send the three weekly images and QA spreadsheet to NCCPM.
Every week, send a copy of the aluminium ball tomosynthesis image, and the 2D and tomosynthesis
images from the Combo exposure to NCCPM for further analysis.
Also send a copy of the Radiographer QA spreadsheet to NCCPM by e-mail.
Monthly thickness check in tomosynthesis mode
This test is an extension of the existing 2D monthly thickness test, and the two would be most easily
carried out together.
Use the same PMMA blocks, compression paddle and thicknesses as are used for the 2D thickness test.
(Record the details of the method used when setting the baseline so that it can be reproduced for future
measurements.) In addition to the conventional 2D Autofilter image, take a tomosynthesis Autofilter image
for each thickness.
DOI: 10.3310/hta19040 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 4
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Gilbert et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
133
Record the kV and mAs for the tomosynthesis exposure on the form/spreadsheet provided and compare
against remedial levels. Where any remedial levels are exceeded, repeat the test to ensure that a mistake
has not been made.
If remedial levels are exceeded or abnormal artefacts are observed then contact the TOMMY physicist
for advice before continuing to use the equipment for patients in the trial.
Notes on quality control tests
Acquisition of patient images for the trial may only take 12 to 18 months, after which time, the TOMMY
trial requirements for QC on the X-ray units may cease, but QC will need to be continued for the reporting
monitors until reading of the images for the trial has finished at the centre. When patient image
acquisition has finished, weekly reporting of QC results to NCCPM will not be required and monthly
reports of monitor QC to NCCPM will suffice.
Monitors
Daily checks on acquisition and reporting monitors (NHSBSP 0702 section 2.1)
Monthly test of reporting monitors (NHSBSP 0702 section 2.2)
NHSBSP 0702 appears a little ambiguous regarding the need for the QC radiographer to have a lightmeter
to measure ambient light levels at the reporting monitor. If a lightmeter is not available and not normally
used for this test, then the QC radiographer needs to be aware of the ambient light levels measured
by the physicist, and the conditions required to keep the ambient light below the 10 lux limit, for example
the closing of blinds and doors, etc. The QC radiographer needs to check that these conditions are being
maintained and take action to reinstate the required conditions, such as closing blinds and reminding users
of the requirements. Where there is any doubt as to whether or not ambient light levels remain with limits,
the physicist should be asked to repeat the measurement with a lightmeter.
X-ray unit
Daily system check in conventional two-dimensional mode (NHSBSP 0702 section 3.1)
The conventional 2D block test may be carried out using the local PMMA usually used for this test
or alternatively the PMMA provided for the tomosynthesis test (without the layer containing the aluminium
ball) may be used if preferred, in order that the 2D and tomo test images may be conveniently carried
out sequentially as a combo exposure.
Ensure that the mean pixel value taken from the ROI for SNR calculation is the corrected value from which
the offset has been subtracted.
The daily 2D image should also be checked for artefacts. Press the ‘Actual pixels’ button to bring
the image into full resolution.
*Daily system check in tomosynthesis mode.
Weekly CNR check in conventional 2D mode (NHSBSP 0702 section 3.2). Weekly uniformity check
(NHSBSP 0702 section 3.3).
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Results need not be reported to NCCPM as we will use the 2D image sent to us each week
to assess homogeneity.
Weekly image quality test (NHSBSP 0702 section 4).
Either Tormam or Tormax may be used according to local procedure. Results need not be reported
to NCCPM.
*Weekly remote QC images.
Three images to be sent to NCCPM each week for further analysis.
Weekly detector flat field calibration (according to manufacturer’s instructions).
The manufacturer’s special flat field phantom must be used for this. In order to keep the flatfield phantom
in pristine condition it should not be used for any other tests.
If the calibration fails the advice given in the manufacturer’s QC manual should be followed and,
if not resolved, use of the equipment should be suspended, an engineer called in, and the TOMMY
physicist and NCCPM informed.
Monthly thickness check in conventional 2D mode (NHSBSP 0702 section 3.4).
*Monthly thickness check in tomosynthesis mode.
Combine with 2D monthly thickness checks and for maximum efficiency use combo mode to acquire
the 2D and tomo images.
The only remedial level for this test is for the mAs, which needs to be within 10% of the baseline
assuming that the baseline was set using the same kV. If the kV differs by only 1kV from the
baseline, repeat the exposure using the kV used for baseline. If the result is now satisfactory, record the
new kV and mAs as a supplementary baseline.
Monthly mechanical and safety function tests (NHSBSP 0702 section 7).
According to local procedure. No need to report this to NCCPM.
*Six-monthly geometry calibration for tomosynthesis (according to manufacturer’s instructions).
The Dimensions system should automatically alert the user when this is due.
If the calibration fails the advice given in the manufacturer’s QC manual should be followed and,
if not resolved, use of the equipment for tomosynthesis should be suspended, an engineer called in,
and the TOMMY physicist and NCCPM informed.
Repeat analysis (NHSBSP 0702 section 8).
According to local procedure. No need to report this to NCCPM.
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TABLE 34 Summary of remedial levels for radiographer QC tests
QC test Remedial level
Daily checks on acquisition and reporting monitors
(NHSBSP 0702 section 2.1)
Monitor fails any of the checks
Monthly test of reporting monitors
(NHSBSP 0702 section 2.2)
Monitor fails any of the checks
Daily system check in conventional 2D mode
(NHSBSP 0702 section 3.1)
mAs baseline± 10% (provided kV & filter match baseline)
DDI baseline± 10% SNR baseline ± 20%
Daily system check in tomosynthesis modea mAs baseline±10% (provided kV & filter match baseline)
Any significant abnormal artefacts
Weekly CNR check in conventional 2D mode
(NHSBSP 0702 section 3.2)
CNR± 20%
Weekly uniformity check (NHSBSP 0702 section 3.3) > 10% deviation from mean PV at centre
Any significant artefacts
Weekly image quality test (NHSBSP 0702 section 4) Any significant change from baseline image
Weekly image of test object containing 1mm
aluminium ball in tomosynthesis modea
Any significant change in the appearance of the aluminium ball
and the reconstruction artefacts above and below it
Weekly detector flat field calibration
(according to manufacturer’s instructions)
Calibration failure
Monthly thickness check in conventional 2D mode
(NHSBSP 0702 section 3.4)
For each thickness:
DDI baseline± 10% SNR baseline± 20% CNR baseline± 20%
Monthly thickness check in tomosynthesis modea For each thickness:
mAs± 10% (provided kV matches baseline)
Monthly mechanical and safety function tests(NHSBSP
0702 section 7)
Equipment fails any of the checks
Six-monthly geometry calibration for tomosynthesis
(according to manufacturer’s instructions)a
Calibration failure
DDI, detector dose indicator.
a Denotes tomosynthesis QC test.
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